LITERAT Ë RA - elibrary.lt · 116 25. Bishayee A., Sarkar A., Chatterjee M. (2000). Further...

114

LITERAT RA

1. Agus D.B., Vera J.C., Golde D.W. (1999). Stromal cell oxidation: a mecha-nism by which tumors obtain vitamin C. Cancer Res., 59(18), 4555-4558.

2. Ahmed M.I., Fayed S.T., Hossein H., Tash F.M. (1999). Lipid peroxidationand antioxidant status in human cervical carcinoma. Dis. Markers, 15(4), 283-291.

3. Alaejos M.S., Diaz Romero F.J., Diaz Romero C. (2000). Selenium and can-cer: some nutritional aspects. Nutrition, 16(5), 376-383.

4. Allen R.G., Balin A.K. (2003). Effects of oxygen on the antioxidant re-sponses of normal and transformed cells. Exp. Cell Res., 289(2), 307-316.

5. Alvarez R.D., Conner M.G., Weiss H., Klug P.M., Niwas S., Manne U., Ba-cus J., Kagan V., Sexton K.C., Grubbs C.J., Eltoum I.E., Grizzle W.E. (2002). Theefficacy of 9-cis-retinoic acid (aliretinoin) as a chemopreventive agent for cervicaldysplasia: results of a randomized double-blind clinical trial. Cancer Epidemiol.Biomarkers Prev., 12(2), 114-119.

6. Ambrosone C.B., Freudenheim J.L., Thompson P.A., Bowman E., Vena J.E.,Marshall J.R., Graham S., Laughlin R., Nemoto T., Shields P.G. (1999). Manganesesuperoxide dismutase (MnSOD) genetic polymorphisms, dietary antioxidants, andrisk of breast cancer. Cancer Res., 59(3), 602-606.

7. Ambs S., Bennett W.P., Merriam W.G., Ogunfusika M.O., Oser S.M., Har-rington A.M., Shields P.G., Felley-Bosco E., Hussain S.P., Harris C.C. (1999). Re-lationship between p53 mutations and inducible nitric oxide synthase expression inhuman colorectal cancer. J. Natl. Cancer Inst., 91(1), 86-88.

8. Ames B. N., Gold L.G. (1996). The causes and prevention of cancer. AnOverview. In: Accomplishments in Cancer Research, 1995, Lipincoft-Raven, Phil-adelphia, New York, 70-91.

9. Anderson W.F., Hawk E., Berg C.D. (2001). Secondary chemoprevention ofupper aerodigestive tract tumors. Seminars in Oncology, 28(1), 106-120.

10. Arnold A.M., Browman G.P., Levine M.N., D’Souza T., Johnstone B., Sk-ingley P., Turner-Smith L., Cayco R., Booker L., Newhouse M., et al. (1992). Theeffect of the synthetic retinoid etretinate on sputum cytology: results from a ran-domised trial. Br. J. Cancer, 65(5), 737-743.

ANTIOKSIDANTAI ONKOLOGIJOJE

115

11. Arthur J.R. (2000). The glutathione peroxidases. Cell. Mol. Life Sci.,57(13-14), 1825-1835.

12. Athar M. (2002). Oxidative stress and experimental carcinogenesis. IndianJ. Exp. Biol., 40(6), 656-667.

13. Atko ius V. (2000). Lietuvos spindulin terapija - 1999. Medicina, 36(8),847-849.

14. Balansky R.M., De Flora S. (2004). Interaction between N-acetylcysteineand sodium selenite in modulating the clastogenicity of uretane and 2-acetylami-nofluorene in mice. Int. J. Cancer, 108(1), 158-161.

15. Barone J., Taioli E., Hebert J.R., Wynder E.L. (1992). Vitamin supplementuse and risk for oral and esophageal cancer. Nutr. Cancer, 18(1), 31-41.

16. Barqawi A., Thomson J.M., Crawford E.D. (2004). Prostate cancer chemo-prevention: an overview of United States trials. J. Urol., 171, S5-S8.

17. Bartsch H., Nair J. (2002). Potential role of lipid peroxidation derivedDNA damage in human colon carcinogenesis: studies on exocyclic base adducts asstable oxidative stress markers. Cancer Detect. Prev., 26(4), 308-312.

18. Behne D., Pfeifer H., Rothlein D., Kyriakopoulos A. (2000). Cellular andsubcellular distribution of selenium and selenoproteins. In: Roussel A.M., FavierA., Anderson R.A., eds. Trace elements in man and animals 10: proceedings of thetenth international symposium on trace elements in man and animals. New York:Plenum Press, 29-33.

19. Benner S.E., Winn R.J., Lippman S.M., Poland J., Hansen K.S., LunaM.A., Hong W.K. (1993). Regression of oral leucoplakia with alpha-tocopherol: acommunity clinical oncology program chemoprevention study. J. Natl. CancerInst., 85(1), 44-47.

20. Beno I., Klvanova J., Magalova T., Brtkova A. (2000). Blood levels of nat-ural antioxidants in gastric and colorectal precancerous lesions and cancers in Slo-vakia. Neoplasma, 47(1), 37-40.

21. Berenblum I. (1929). Modifying influence of dichlorethyl sulphide on theinduction of tumours in mice by tar. J. Pathol. Bacteriol., 32, 425-434.

22. Bergamini C.M., Gambetti S., Dondi A., Cervelati C. (2004). Oxygen, re-active oxygen species and tissue damage. Curr. Pharm. Des., 10(14), 1611-1626.

23. Bhosle S.M., Pandey B.N., Hiulgol N.G., Mishra K.P. (2002). Membraneoxidative damage and apoptosis in cervical carcinoma cells patients after radiationtherapy. Methods Cell Sci., 24(1-3), 65-68.

24. Bialy T.L., Rothe M.J., Grant-Kels J.M. (2002). Dietary factors in the pre-vention and treatment of nonmelanoma skin cancer and melanoma. Dermatol. Sur.,28(12), 1143-1152.

LITERAT RA

116

25. Bishayee A., Sarkar A., Chatterjee M. (2000). Further evidence for chemo-preventive potential of beta-carotene against experimental carcinogenesis: dieth-ylnitrozamine-initiated and phenobarbital-promoted hepatocarcinogenesis is pre-vented more effectively by beta-carotene than by retinoic acid. Nutr. Cancer, 37(1),89-98.

26. Bize I.B., Oberley L.W., Morris H.P. (1980). Superoxide dismutase and su-peroxide radical in Morris hepatomas. Cancer Res., 40, 3685-3693.

27. Black H.S. (2002). Pro-oxidant and anti-oxidant mechanism(s) of BHT andβ carotene in photocarcinogenesis. Frontiers in Bioscience, 7, 1044-1055.

28. Blanchard B., Pompon D., Ducrocq C. (2000). Nitrosation of melatonin bynitric oxide and peroxynitrite. J. Pineal Res., 29(3), 184-192.

29. Blask D.E. (1997). The melatonin rhythm in cancer patients. In: Melatoninin psychiatric and neoplastic disorders (ed. Shafi M.). Washington, DC, AmericanPsychiatric Press, 257-275.

30. Blask D.E., Lemus-Wilson A.M., Wilson S.T., et al. (1993). Neurohormon-al modulation of cancer growth by pineal melatonin. In: Melatonin and the pinealgland: from basic science to clinical application. Touitou Y., Arendt J., Pever P.(eds.). Amsterdam, the Netherlands, Elsevier, 303-310.

31. Blot W.J., Li J.Y., Taylor P.R., Guo W., Dawsey S., Wang G.Q., Yang C.S.,Zheng S.F., Gail M., Li G.Y., Yu Y., Liu B.Q., Tangrea J., Sun Y.H., Liu F., Fraume-ni J.F., Zhang Y.H., Li B. (1993). Nutrition intervention trials in Linxian, China:supplementation with specific vitamin/mineral combinations, cancer incidence anddisease-specific mortality in the general population. J. Natl. Cancer Inst., 85(18),1483-1492.

32. Bloznelyt L., eburkovas O., Dambrauskait E., Navickien J., Pa-kalniškien L. (2000). Odos ir gleivini navik aplikacinis fotodinaminis gydymas.Medicina, 36(8), 800-804.

33. Bohm F., Edge R., McGarvey D.J., Truscott T.G. (1998). β-Carotene withvitamins E and C offers synergistic cell protection against NOx. FEBS Lett.,436(3), 387-389.

34. Bolla M., Lefur R., Ton Van J., Domenge C., Badet J.M., Koskas Y.,Laplanche A. (1994). Prevention of second primary tumours with etretinate insquamous cell carcinoma of the oral cavity and propharynx: results of a multicentredouble blind randomised study. Eur. J. Cancer, 30, 767-772.

35. Bostwick D.G., Alexander E., Singh R., Shan A., Qian J., Santella R.,Oberley L.W., Yan T., Zhong W., Jiang X., Oberley T.D. (2000). Antioxidant en-zyme expression and reactive oxygen species damage in prostatic intraepithelialneoplasia and cancer. Cancer, 89(1), 123-134.

LIETUVOS MOKSLAS

117

36. Bounous G., Molson J.H. (2003). The antioxidant system. Anticancer Res.,23(2B), 1411-1415.

37. Bracke M.E., Depypere H.T., Boterberg T., Van Marck V.L., VennekensK.M., Vanluchene E., Nuytinck M., Serreyn R., Mareel M.M. (1999). Influence oftangeretin on tamoxifen’s therapeutic benefit in mammary cancer. J. Natl. CancerInst., 91(4), 354-359.

38. Buetther G.R. (1993). The pecking order of radicals and antioxidants: lipidperoxidation, a-tocopherol and ascorbate. Arch. Biochem. Biophys., 300(2), 535-543.

39. Burstein H.J., Gelber S., Guadagnoli E., Weeks J.C. (1999). Use of alterna-tive medicine by women with early-stage breast cancer. N. Engl. J. Med., 340,1733-1739.

40. Bushman J.L. (1998). Green tea and cancer in humans: a review of the lit-erature. Nutr. Cancer, 31(3), 151-159.

41. Bussey H.J.R., DeCosse J.J., Deschner E.E., Eyers A.A., Lesser M.L.,Morson B.C., Ritchie S.M., Thomson J.P., Wadsworth J. (1982). A randomized trialof ascorbic acid in polyposis coli. Cancer, 50(7), 1434-1439.

42. Butterworth C.E. (1992). Effect of folate on cervical cancer: synergismamong risk factors. Ann. NY. Acad. Sci., 669, 293-299.

43. Cadet J., Delatour T., Douki T., Gasparatto D., Rouget J., Ravanat J.-L.,Sauvaigo S. (1999). Hydroxyl radicals and DNA base damage. Mutat. Res., 424(1-2), 9-21.

44. Cameron E. (1991). Protocol for the use of vitamin C in the treatment ofcarcinoma. Med. Hypotheses, 36(3), 190-194.

45. Campbell K.C., Larsen D.L., Meech R.P., Rybak L.P., Hughes L.F. (2003).Glutathione ester but not glutathione protects against cisplatin-induced ototoxicityin a rat model. J. Am. Acad. Audiol., 14(3), 124-133.

46. Campbell S., Stone W., Wholey S., Krishnan K. (2003). Development ofgamma (gamma)-tocopherol as a colorectal cancer chemopreventive agent. Crit.Rev. Oncol. Hematol., 47(3), 249-259.

47. Casas A., Perotti C., Fukuda H., del C Batlle A.M. (2002). Photodynamictherapy of activated and resting lymphocytes and its antioxidant adaptive response.Lasers Med. Sci., 17(1), 42-50.

48. Cascinu S., Cordella L., Del Ferro E., Fronzoni M., Catalano G. (1995).Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy inadvanced gastric cancer: a randomized double-blind placebo-controlled trial. J.Clin. Oncol., 13(1), 26-32.


118

49. Cavenee W.K., White R.L. (1995). The genetic basis of cancer. Sci. Am.,272 (3), 50-57.

50. Cenas N., Nivinskas H., Anusevicius Z., Sarlauskas J., Lederer F., ArnerE.S. ( 2003). Interactions of quinines with thioredoxin reductase: a challenge to theantioxidant role of the mammalian selenoprotein. J. Biol. Chem., 279(4), 2583-2592.

51. Cerea G., Vaghi M., Ardizzoia A., Villa S., Bucovec R., Mengo S., GardaniG., Tancini G., Lissoni P. (2003). Biomodulation of cancer chemotherapy for meta-static colorectal cancer: a randomized study of weekly low-dose irinotecan aloneversus irinotecan plus the oncostatic pineal hormone melatonin in metastatic col-orectal cancer patients progressing on 5-fluorouracil-containing combinations. An-ticancer Res., 23(2C), 1951-1954.

52. erniauskas L., Grici t L. (1989). Vlijanije SeO2 i askorbinovoj kislotyna kancerogenez vyzvannyj sovmestnym deistvijem stirola i benz(a)pirena, a takženitrozonornikotina i nitrozometilamina u krys linii Wistar. Exp. Oncol., 11(5), 3(rus.).

53. erniauskien L.R. (1994). Antioksidantiniai vitaminai E ir A: epidemi-ologiniai, klinikiniai ir eksperimentiniai tyrimai. Kaunas: KMA leidykla „Medici-nos akademija“, 93.

54. Cerutti P.A. (1994). Oxy-radicals and cancer. Lancet, 344(8926), 862-863.55. Chang Y.S., Seo E.-K., Gyllenhaal C., Block K.I. (2003). Panax ginseng: a

role in cancer therapy? Integr. Cancer Therapies, 2(1), 13-33.56. Cheeseman K.H., Burton C.N., Ingold K.U., Slater T.F. (1984). Lipid per-

oxidation and lipid antioxidants in normal and tumor cells. Toxicol. Pathol., 12(3),235-239.

57. Chevion S., Or R., Berry E.M. (1999). The antioxidant status of patientssubjected to total body irradiation. Biochem. Mol. Biol. Int., 47(6), 1019-1027.

58. Chiang C.D., Song E.J., Yang V.C., Chao C.C. (1994). Ascorbic acid in-creases drug accumulation and reverses vincristine resistance of human non-small-cell lung-cancer cells. Biochem. J., 301(3), 759-764.

59. Childers J.M., Chu J., Voigt L.F., Feigl P., Tamimi H.K., Franklin E.W., Al-berts D.S., Meyskens F.L. Jr. (1995). Chemoprevention of cervical cancer with fol-ic acid: a phase III Southwest Oncology Group Intergroup study. Cancer Epidemi-ol. Biomarkers Prev., 4(2), 155-159.

60. Ching S., Ingram D., Hahnel R., Beilby J., Rossi E. (2002). Serum levels ofmicronutrients, antioxidants and total antioxidant status predict risk of breast can-cer in a case control study. J. Nutr., 132(2), 303-306.

LITERAT RA

119

61. Cho E., Spiegelman D., Hunter D.J., Chen W.Y, Zhang S.M., Colditz G.A.,Willett W.C. (2003). Premenopausal intakes of vitamins A, C, and E, folate andcarotenoids, and risk of breast cancer. Cancer Epidemiol. Biomarkers Prev., 12(8),713-720.

62. Chung F.L., Nath R.G., Nagao M., Nishikawa A., Zhou G.D., Randerath K.(1999). Endogenous formation and significance of 1,N2-propanodeoxyguanosineadducts. Mutat. Res., 424(1-2), 71-81.

63. Chung-man Ho J., Zheng S., Comhair S.A., Farver C., Erzwum S.C.(2001). Different expression of manganese superoxide dismutase and catalase inlung cancer. Cancer Res., 61(23), 8578-8585.

64. Cirak B., Inci S., Palaoglu S., Bertan V. (2003). Lipid peroxidation in cere-bral tumors. Clin. Chim. Acta, 327(1-2), 103-107.

65. Clark L.C., Combs G.F., Turnbull B.W., Slate E.H., Chalker D.K., Chow J.,Davis L.S., Glover R.A., Graham G.F., Gross E.G., Krongrad A., Lesher J.L. Jr.,Park H.K., Sanders B.B. Jr., Smith C.L., Taylor J.R. (1996). Effects of seleniumsupplementation for cancer prevention in patients with carcinoma of the skin. Arandomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA,276(24), 1957-1963.

66. Clemens M.R., Waladkhami A.B., Bublitz K., Ehninger G., Gey K.F.(1997). Supplementation with antioxidants prior to bone morrow transplantation.Nien Klin. Nochenschr., 109, 771-776.

67. Cobbs C.S., Levi D.S., Aldape K., Izrael M.A. (1996). Manganese super-oxide dismutase expression in human central nervous system tumors. Cancer Res.,56(14), 3192-3195.

68. Cohen M., Bhagavan H.N. (1995). Ascorbic acid and gastrointestinal can-cer. J. Am. Coll. Nutr., 14(6), 565-578.

69. Cohen V., Khuri F.R. (2004). Chemoprevention of lung cancer. Curr. Opin.Pulm. Med., 10(4), 279-283.

70. Cole W.C., Prasad K.N. (1998). Heterogeneity of commercial -carotenepreparations: correlation with biological activities. In.: Prasad K.N. Cole W.C.(eds.): “Cancer and Nutrition”. Amsterdam: IOS Press, 99-104.

71. Combs G.F.Jr., Clark L.C., Turnbull B.W. (2001). An analysis of cancerprevention by selenium. Biofactors, 14(1-4), 153-159.

72. Conklin K.A. (2000). Dietary antioxidants during cancer chemotherapy:impact on chemotherapeutic effectiveness and development of side effects. Nutr.Cancer. 37(1), 1-18.

LIETUVOS MOKSLAS

120

73. Copper M.P., Klaassen I., Teerlink T., Snow G.B., Braakhuis B.J. (1999).Plasma retinoid levels in head and neck cancer patients: a comparison with healthycontrols and the effect of retinyl palmitate treatment. Oral. Oncol., 35(1), 40-44.

74. Cos S., Sanchez-Barcelo E.J. (1995). Melatonin inhibition of MCF-7 hu-man breast-cancer cells growth: influence of cell proliferation rate. Cancer Lett.,93(2), 207-212.

75. Costa A., Formelli F., Chiesa F., Decensi A., De Palo G., Veronesi U.(1994). Prospects of chemoprevention of humans cancers with synthetic retinoidfenretinide. Cancer Res., 54(7 Suppl.), 2032S-2037S.

76. Creagan E.T., Moertel C.G., O’Fallon J.R., Schutt A.J., O’Connell M.J.,Rubin J., Frytak S. (1979). Failure of high-dose vitamin C (ascorbic acid) therapyto benefit patients with advanced cancer. N. Engl. J. Med., 301(13), 687-690.

77. Dalhoff K., Ranek L., Mantoni M., Poulsen H.E. (1992). Glutathione treat-ment of hepatocellular carcinoma. Liver, 12(5), 341-343.

78. Das U.N. (1992). Asunsaturated fatty acids as potencial anti-mutagenic, tu-morocidal and anti-metastatic agents. Asia Pacific J. Pharmacol., 7, 305-327.

79. Das U.N. (1999). Essential fatty acids, lipid peroxidation and apoptosis.Prostaglandins Leukot. Essent. Fatty Acids, 61(3), 157-163.

80. Das U.N. (2002). A radical approach to cancer. Med. Sci. Monit., 8, RA79-92.

81. De Bono D.P. (1994). Free radicals and antioxidants in vascular biology:the roles of reaction kinetics, environment and substrate turnover. Q.J.Med., 87(8),445-53.

82. De Bont R., van Larebeke N. (2004). Endogenous DNA damage in hu-mans: a review of quantitative data. Mutagenesis, 19(3), 169-185.

83. De Klerk N.H., Musk W., Ambrosini G.L., Eccles J.L., Hansen J., OlsenN., Watts V.L., Lund H.G., Pang S.C., Beilby J., Hobbs M.S. (1998). Vitamin A andcancer prevention II. Comparison of the effects of retinol and β-carotene. Int. J.Cancer, 75(3), 362-367.

84. De Maria D., Falchi A.M., Venturino P. (1992). Adjuvant radiotherapy ofthe pelvis with or without reduced glutathione: a randomized trial in patients oper-ated on for endometrial cancer. Tumori, 78(6), 374-376.

85. De Vries N., van Zandwijk N., Pastorino U. (1999). Chemoprevention ofhead and neck and lung (pre)cancer. Recent Results Cancer Res., 151, 13-25.

86. Decensi A., Costa A. (2000). Recent advances in cancer chemoprevention,with emphasis on breast and colorectal cancer. Eur. J. Cancer, 36(6), 694-709.


121

87. De Cosse J.J., Miller H.H., Lesser M.L. (1989). Effect of wheat fiber andvitamins C and E on rectal polyps in patients with familial adenomatous polyposis.J. Natl. Cancer Inst., 81(17), 1290-1297.

88. Delanian S. (1998). Striking regression of radiation-induced fibrosis by acombination of pentoxifylline and tocopherol. Br. J. Radiol., 71(848), 892-894.

89. Delanian S., Porcher R., Balla-Mekias S., Lefaix J.L. (2003). Randomized,placebo-controlled trial of combined pentoxifylline and tocopherol for regressionof superficial radiation-induced fibrosis. J. Clin. Oncol., 21(13), 2545-2550.

90. Demierre M.-F., Nathanson L. (2003). Chemoprevention of melanoma: anunexplored strategy. J. Clin. Oncol., 21(1), 158-165.

91. Depypere H.T., Bracke M.E., Boterberg T., Mareel M.M., Nuytinck M.,Vennekens K., Serreyn R. (2000). Inhibition of tamoxifen’s therapeutic benefit bytangeretin in mammary cancer. Eur. J. Cancer, 36 Suppl 4, S73.

92. Devasagayam T.P., Kamat J.P. (2002). Biological significance of singletoxygen. Indian J. Exp. Biol., 40(6), 680-692.

93. Di Giacomo C., Acquaviva R., Lanteri R., Licata F., Licata A., Vanella A.(2003). Nonproteic antioxidant status in plasma of subjects with colon cancer. Exp.Biol. Med., 228(5), 525-528.

94. Di Giovanni J. (1990). Inhibition of chemical carcinogenesis (Chapter 7).Chemical Carcinogenesis and Mutagenesis II. Springer-Ferlag, Heidelberg, 159-223.

95. Didžiapetrien J. (2004). Lipid peroksidacijos intensyvumo poky iai fo-tosensibilizacin s navik terapijos metu bei derinant fotosensibilizacin navik tera-pij su priešnavikiniu vaistu adriamicinu. Laboratorin medicina, 2(22), 3–6..

96. Didžiapetrien J., Narbutien G., Šukelien D., Prasmickien G., BreivisP., Ruolia J., Žilinskas J. (2000a). Kai kuri biochemini rodikli poky iai gydantligones, sergan ias kiaušidži v žiu. Medicina, 36(8), 865-871.

97. Didžiapetrien J., Prasmickien G., Šukelien D., Gudlevi ien Ž., Žemai-tyt R., Jurgelevi ien V. (2003). Antioksidacin s sistemos b sena sergant gimdoskaklelio v žiu ir esant žmogaus papilomos viruso infekcijai. Sveikatos mokslai, 13,44-47.

98. Didžiapetrien J., Prasmickien G., Šukelien D., Pipirien T. (2000b). Ok-sidacinio streso poky iai gydant citostatikais kr ties v žiu sergan ius ligonius. Me-dicina, 36(8), 855-858.

99. Didžiapetrien J.K., Šukelien D.F., Dži vien D.A., Degutis J.A. (1988).Antikancerogennyje i protivoopucholevyje svoistva nekotorych selenosoder-žaš ych derivatov fenola. Exp. Oncol., 10(6), 57-59 (rus.).

LITERAT RA

122

100. Didžiapetrien J.K., Šukelien D.T., Dži vien D.A., Degutis J.A. (1987).Protivoopucholevyje i antikancerogennyje svoistva proizvodnych gvajakolseleno-voj kisloty. Chimiko farmacevti eskij žurnal, 10, 1195-1199 (rus.).

101. Dik i t R., Abaravi ius A., Ku inskien Z., Grigali nien I., Vait-kevi ien Z., Petraitis R. (1999). Apie E ir A vitamin nustatymo metodus bei LIV-ICORDIA studijos rezultatus. Laboratorin medicina, 4, 14-17.

102. Dizdaroglu M., Jaruga P., Birincioglu M., Rodriguez H. (2002). Free radi-cal-induced damage to DNA: mechanisms and measurement. Free Radical Bio.Med., 32(11), 1102-1115.

103. Domkien V., Uleckien S., Didžiapetrien J. Grici t L. (2000). Orga-ninio seleno junginio – D-gliukozamino hidroselenato galimo antikancerogeniniopoveikio tyrimai. Medicina, 36(8), 786-797.

104. Dorgan J.F., Sowell A., Swanson S.A., Potischman N., Miller R., Schus-sler N., Stephenson H.E. Jr. (1998). Relationships of serum carotenoids, retinol, al-pha-tocopherol, and selenium with breast cancer risk: results from a prospectivestudy in Columbia, Missouri (United States). Cancer Causes Control, 9(1), 89-97.

105. Dormandy T.L. (1988). In praise of peroxidation. Lancet, 2(8620), 1126-1128.

106. Drisko J.A., Chapman J., Hunter V.J. (2003). The use of antioxidant ther-apies during chemotherapy. Gynecol. Oncol., 88(3), 434-439.

107. Droge W. (2002). Free radicals in the physiological control of cell func-tion. Physiol. Rev., 82(1), 47-95.

108. Duchesne G.M., Hutchinson L.K. (1995). Reversible changes in radiationresponse induced by all-trans retinoic acid. Int. J. Radiat. Oncol. Biol. Phys., 33(4),875-880.

109. Duensing S., Munger K. (2004). Mechanisms of genomic instability inhuman cancer: insights from studies with human papillomavirus oncoproteins. Int.J. Cancer, 109(2), 157-162.

110. Durak I., Canbolat O., Kavutcu M., Ozturk H.S., Yurtarslani Z. (1996).Activities of total, cytoplasmic, and mitochondrial superoxide dismutase enzymesin sera and pleural fluids from patients with lung cancer. J. Clin. Lab. Anal., 10(1),17-20.

111. El-Bayoumy K. (2001). The protective role of selenium on genetic dam-age and on cancer. Mutat. Res., 475(1-2), 123-139.

112. El-Bayoumy K., Upadhyaya P., Chae Y.H., Sohn O.S., Rao C.V., Fiala E.,Reddy B.S. (1995). Chemoprevention of cancer by organoselenium compounds. J.Cell. Biochem. Suppl., 22, 92-100.

LIETUVOS MOKSLAS

123

113. Emanuel N.M. (1985). Kinetics and free radical mechanisms of aging andcarcinogenesis. Age-related factors to carcinogenesis. Lyon, IARC Sci. Publ., 58,127-150.

114. Emanuel N.M., Lipchina L.P. (1958). Leukemia in mice and main featuresof its development under the action of inhibitors of chain oxidative processes.Dokl. AN SSSR, 121, 141-144 (rus.).

115. Epperly M.W., Kagan V.E., Sikora C.A., Gretton J.E., Defilippi S.J., Bar-Sagi D., Greenberger J.S. (2001). Manganese superoxide dismutase-plasmid/lipo-some (MnSOD-PL) administration protects mice from esophagitis associated withfractionated radiation. Int. J. Cancer, 96(4), 221-231.

116. Erhola M., Nieminen M.M., Kellokumpu-Lehtinen P., Huusari H., AlankoK., Metsa-Ketela T., Alho H. (1998). Effects of surgical removal of lung cancer ontotal plasma antioxidant capacity in lung cancer patients. J. Exp. Clin. Cancer Res.,17(2), 219-225.

117. Faber M., Coudray C., Hida H., Mousseau M., Favier A. (1995). Lipidperoxidation products, and vitamin and trace element status in patients with cancerbefore and after chemotherapy, including adriamycin. Biol. Trace Elem. Res., 47(1-3), 117-123.

118. Fairfield K.M., Fletcher R.H. (2002). Vitamins for chronic disease pre-vention in adults. Jama, 287(23), 3116-3126.

119. Fairfield K.M., Hankinson S.E., Rosner B.A., Hunter D.J., Colditz G.A.,Willett W.C. (2001). Risk of ovarian carcinoma and consumption of vitamins A, Cand E and specific carotenoids: a prospective analysis. Cancer, 92(9), 2318-2326.

120. Fang Y.-Z., Yang S., Wu G. (2002). Free radicals, antioxidants, and nutri-tion. Nutrition, 18(10), 872-879.

121. Finkel T. (2000). Redox-dependent signal transduction. FEBS Lett.,476(1-2), 52-54.

122. Floyd R.A., Watson J.J., Wong P.K., Altmiller D.M., Rickard R.A.(1986). Hydroxyl free radical adduct of deoxyguanosine: sensitive detection andmechanisms of formation. Free Radical Res. Commun., 1(3), 163-172.

123. Folkers K., Brown R., Judy W.V., Morita M. (1993). Survival of cancerpatients on therapy with coenzyme Q10. Biochem. Biophys. Res. Commun.,192(1), 241-245.

124. Follen M., Meyskens F.L. Jr., Alvarez R.D., Walker J.L., Bell M.C.,Storthz K.A., Sastry J., Roy K., Richards-Kortum R., Cornelison T.L. (2003). Cer-vical cancer chemoprevention, vaccines, and surrogate endpoint biomarkers. Can-cer, 98(9), 2044-2051.


124

125. Follen M., Vlastos A.T., Meyskens F.L. Jr., Atkinson E.N., SchottenfeldD. (2002). Why phase II trials in cervical chemoprevention are negative: what havewe learned? Cancer Causes Control, 13(9), 855-887.

126. Fong L.Y., Nguyen V.T., Farber J.L. (2001). Esophageal cancer preven-tion in zinc-deficient rats: rapid induction of apoptosis by replenishing zinc. J. Natl.Cancer Inst., 93(20), 1525-1533.

127. Fortini P., Pascucci B., Parlanti E., D’Errico M., Simonelli V., Dogliotti E.(2003). 8-Oxoguanine damage: at the crossroad of alternative repair pathways. Mu-tat. Res., 531(1-2), 127-139.

128. Furuya Y., Yamamoto K., Kohno N., Ku Y., Saitoh Y. (1994). 5-Fluorou-racil attenuates an oncostatic effect of melatonin on estrogen-sensitive humanbreast cancer cells (MCF7). Cancer Lett., 81(1), 95-98.

129. Gandini S., Merzenich H., Robertson C., Boyle P. (2000). Meta-analysisof studies on breast cancer risk and diet: the role of fruit and vegetable consumptionand the intake of associated micronutrients. Eur. J. Cancer, 36(5), 636-646.

130. Garewal H.S., Katz R.V., Meyskens F., Pitcock J., Morse D., Friedman S.,Peng Y., Pendrys D.G., Mayne S., Alberts D., Kiersch T., Graver E. (1999). β Caro-tene produces sustained remissions in patients with oral leucoplakia. Arch. Oto-laryngol. Head Neck Surg., 125(12), 1305-1310.

131. Garewal H.S., Meyskens F.L.Jr., Killen D., Reeves D., Kiersch T.A.,Elletson H., Strosberg A., King D., Steinbronn K. (1990). Response of oral leuco-plakia to beta-carotene. J. Clin. Oncol., 8(10), 1715-1720.

132. Gerber M., Astre C., Segala C., Saintot M., Scali J., Simony-LafontaineJ., Grenier J., Pujol H. (1997). Tumor progression and oxidant-antioxidant status.Cancer Lett., 114(1-2), 211-214.

133. Ghielmini M., Pagani O., de Jong J., Pampallona S., Conti A., MaestroniG., Sessa C., Cavalli F. (1999). Double-blind randomized study on the myelopro-tective effect of melatonin in combination with carboplatin and etoposide in ad-vanced lung cancer. Br. J. Cancer, 80(7), 1058-1061.

134. Giacosa A., Filiberti R., Hill M.J., Faivre J. (1997). Vitamins and cancerchemoprevention. Eur. J. Cancer Prev., 6 (Suppl. 1), S47-S54.

135. Giovannucci E. (1999). Tomatoes, tomato-based products, lycopene, andcancer: review of the epidemiologic literature. J. Nat. Cancer Inst., 91(4), 317-331.

136. Giuliano A.R., Papenfuss M., Nour M., Canfield L.M., Schneider A.,Hatch K. (1997). Antioxidant nutrients: associations with persistent human papillo-mavirus infection. Cancer Epidemiol. Biomarkers Prev., 6(11), 917-23.

LITERAT RA

125

137. Gonenc A., Ozkan Y., Torun M., Simsek B. (2001). Plasma malondialde-hyde (MDA) levels in breast and lung cancer patients. J. Clin. Pharm. Ther., 26(2),141-144.

138. Gopalakrishna R., Gundimeda U., Chen Z.H. (1995). Vitamin E succinateinhibits protein kinase C: correlation with its unique inhibitory effects on cellgrowth and transformation. In: Presad K.N., Santamaria L., Williams R.M. (eds.):Nutrients in Cancer Prevention and Treatment. Totowa, NJ: Human Press, 21-37.

139. Greenberg E.R., Baron J.A., Tosteson T.D. (1994). A clinical trial of anti-oxidant vitamins to prevent colorectal adenoma. Polyp Prevention Study Group. N.Engl. J. Med., 331(3), 141-147.

140. Greenwald P. (2002). Cancer chemoprevention. B.M.J., 324(7339), 714-718.

141. Greenwald P., Lieberman R. (2001). Chemoprevention trials for prostatecancer. In: Chung L., Isaacs W., Simons J. (eds). Prostate cancer in 21st Centery.Humana Press Inc., Totowa, NY, 499-518.

142. Greenwald P., Milner J.A., Anderson D.E., McDonald S.S. (2002). Micro-nutrients in cancer chemoprevention. Cancer Metast. Rev., 21(3-4), 217-230.

143. Grici t L, Didžiapetrien J., Uleckien S., Prasmickien G., ŠukelienD., Žemaityt R., Domkien V. (2002).The experimental studies of ethyl alcoholinfluence on antioxidative and anticarcinogenic properties of β-carotene. Actamedica Lituanica, 9, 7-12.

144. Grici t L., Adomaitien D. (1998). Kancerogenez ir v žio biologija.Vilnius: Leidybos centras,324.

145. Grici t L., Uleckien S., Didžiapetrien J. (2001). V žio profilaktikospagrindai (rekomendacijos bendrosios praktikos gydytojams). Vilnius: LKVLD,35.

146. Guo G., Yan-Sanders Y., Lyn-Cook B.D., Wang T., Tamae D., Ogi J.,Khaletskiy A., Li Z., Weydert C., Longmate J.A., Huang T.T., Spitz D.R., OberleyL.W., Li J.J. (2003). Manganese superoxide dismutase-mediated gene expression inradiation-induced adaptive responses. Mol. Cell. Biol., 23(7), 2362-2378.

147. Gupta R.C., Reddy M.V., Randerath K. (1982). 32P-post-labeling analysisof non-radioactive aromatic carcinogen-DNA adducts. Carcinogenesis, 3(9), 1081-1092.

148. Gustin D.M., Brenner D.E. (2002). Chemoprevention of colon cancer:Current status and future prospects. Cancer Metast. Rev., 21(3-4), 323-348.

149. Hahn S.M., Mitchell J.B., Shacter E. (1997). Tempol inhibits neutrophiland hydrogen peroxide-mediated DNA damage. Free Radic. Biol. Med., 23(6),879-884.

LIETUVOS MOKSLAS

126

150. Hall E.J. (2000). Radiobiology for the radiologists. Lippincott-Williams-Wilkins, 588.

151. Halliwell B.A. (2000). A super way to kill cancer cells? Nature Med.,6(10), 1105-1106.

152. Halperin E.C., Gaspar L., George S., Darr D., Pinell S. (1993). A double-blind randomised prospective trial to evaluate topical vitamin C solution for theprevention of radiation dermatitis. CNS Cancer Consortium. Int. J. Radiat. Oncol.Biol. Phys., 26(3), 413-416.

153. Hampton M.B., Fadeel B., Orrenius S. (1998). Redox regulation of thecaspases during apoptosis. Ann. NY Acad. Sci., 854, 328-335.

154. Han J., Jiao L., Lu Y., Sun Z., Gu Q.M., Scanlon K.J. (1990). Evaluationof N-4-(hydroxycarbophenyl) retinamide as a cancer prevention agent and as a can-cer chemotherapeutic agent. In vivo, 4(3), 153-160.

155. Hansson L., Nyren O., Bergstrom R., Wolk A., Lindgren A., Baron J., Ad-ami H.O. (1994). Nutrients and gastric cancer risk. A population-based case-con-trol study in Sweden. Int. J. Cancer, 57(5), 638-644.

156. Heinonen O.P., Albanes D. (1994). The effect of vitamin E and β-caroteneon the incidence of lung cancer and other cancers in male smokers. N. Engl. J.Med., 330(15), 1029-1035.

157. Hellstrand K., Hermodsson S., Naredi P., Mellquist U.H., Brune M.(1998). Histamine and cytokine therapy. Acta Oncol., 37(4), 347-353.

158. Hennekens C.H., Buring J.E., Manson J.E., Stampfer M., Rosner B.,Cook N.R., Belanger C., LaMotte F., Gaziano J.M., Ridker P.M., Willett W., PetoR. (1996). Lack of effect of long-term supplementation with beta-carotene on theincidence of malignant neoplasms and cardiovascular disease. N. Engl. J. Med.,334(18), 1145-1149.

159. Hercberg S., Galan P., Preziosi P., Malvy M., Briancon S., Ait H.M., Ra-him B., Favier A. (2002). The SU.VI.MAX trial on antioxidants. IARC Sci. Publ.,156, 451-455.

160. Hirayama T. (1986). Current aspects of cancer epidemiology. Plenary lec-ture: 14th Int. Cancer Congr. Budapest, 1, 2.

161. Hoffman M.E., de Mello Filho A.C., Meneghim R. (1984). Correlationbetween cytotoxic effect of hydrogen peroxide and the yield of DNA strand breaksin cells of different species. Biochim. Biophys. Acta, 781(3), 234-238.

162. Hofseth L.J., Hussain S.P., Wogan G.N., Hariss C.C. (2003). Nitric oxidein cancer and chemoprevention. Free Radical. Bio. Med., 34(8), 955-967.


127

163. Holland J.F., Bast R.C., Morton D.L., Frei E., Kufe D.W., WeichselbaumR.R., eds. (1997). Cancer Medicine. 4th Ed. Baltimore, MD: Williams and Wilk-ens.

164. Hong W.K., Endicott J., Itri L.M., Doos W., Batsakis J.G., Bell R., Fo-fonoff S., Byers R., Atkinson E.N., Vaughan C., Toth B.B., Kramer A., DimeryI.W., Skipper P., Strong S. (1986). 13-cis-Retinoic acid in the treatment of oral leu-coplakia. N. Engl. J. Med., 315(24), 1501-1505.

165. Hong W.K., Lippman S.M., Itri L.M., Karp D.D., Lee J.S., Byers R.M.,Schantz S.P., Kramer A.M., Lotan R., Peters L.J., Dimery I.W., Brown B.N.,Goepfert H. (1990). Prevention of secondary primary tumors with isotretinoin insquamous-cell carcinoma of the head and neck. N. Engl. J. Med., 323(12), 795-801.

166. Hong W.K., Sporn M.B. (1997). Recent advances in chemoprevention ofcancer. Science, 278(5340), 1073-1077.

167. Hristozov D., Gadjeva V., Vlaykova T., Dimitrov G. (2001). Evaluationof oxidative stress in patients with cancer. Arch. Physiol. Biochem., 109(4), 331-336.

168. Hu Y.J., Chen Y., Zhang Y.Q., Zhou M.Z., Song X.M., Zhang B.Z., LuoL., Xu P.M., Zhao Y.N., Zhao Y.B., Cheng G. (1997). The protective role of seleni-um on the toxicity of cisplatin-contained chemotherapy regimen in cancer patients.Biol. Trace Elem. Res., 56(3), 331-341.

169. Huang P., Feng L., Oldham E.A., Keating M.J., Plunkett W. (2000). Su-peroxide dismutase as a target for the selective killing of cancer cells. Nature,407(6802), 390-395.

170. Huang Y.L., Sheu J.Y., Lin T.H. (1999). Association between oxidativestress and changes of trace elements in patients with breast cancer. Clin. Biochem.,32(2), 131-136.

171. Hunter T. (1997). Oncoproteins network. Cell, 88, 333-346.172. Hussain S.P., Hoflseth L.J., Harris C.C. (2003). Radical causes of cancer.

Nature Reviews Cancer, 3(4), 276-285.173. Hussain S.P., Raja K., Amstad P.A., Sawyer M., Trudel L.J., Wogan G.N.,

Hofseth L.J., Shields P.G., Billiar T.R., Trautwein C., Hohler T., Galle P.R., PhillipsD.H., Markin R., Marrogi A.J., Harris C.C. (2000). Increased p53 mutation load innoncancerous colon tissue from ulcerative colits: a cancer –prone chronic inflam-matory disease. Cancer Res., 60(13), 3333-3337.

174. Ianas O., Olinescu R., Badescu I. (1991). Melatonin involvement in oxi-dative processes. Endocrinologie, 29(3-4), 147-153.

175. Iarussi D., Auricchio U., Agretto A., Murano A., Giuliano M., Casale F.,Indolfi P., Iacono A. (1994). Protective effect of coenzyme Q10 on anthracyclines

LITERAT RA

128

cardiotoxicity: control study in children with acute lymphoblastic leukemia andnon-Hodgkin lymphoma. Mol. Aspects Med., 15 Suppl., 207-212.

176. Ikushima T., Aritomi H., Morisita J. (1996). Radioadaptive response: effi-cient repair of radiation-induced DNA damage in adapted cells. Mutat. Res.,358(2), 193-198.

177. Ip C., Dong Y., Ganther H.E. (2002). New concepts in selenium chemo-prevention. Cancer Metast. Rev., 21(3-4), 281-289.

178. Ip C., Hayes C., Budnick R.M., Ganther H.E. (1991). Chemical form ofselenium, critical metabolites, and cancer prevention. Cancer Res., 51(2), 595-600.

179. Israel K., Yu W., Sanders B.G., Kline K. (2000). Vitamin E succinate in-duces apoptosis in human prostate cancer cells: role for Fas in vitamin E succinate-triggered apoptosis. Nutr. Cancer, 36(1), 90-100.

180. Jaakkola K., Lahteenmaki P., Laakso J., Harju E., Tykka H., Mahlberg K.(1992). Treatment with antioxidant and other nutrients in combination with chemo-therapy and irradiation in patients with small-cell lung cancer. Anticancer Res.,12(3), 599-606.

181. Jacobs E.J., Connell C.J., McCullough M. L., Chao A., Jonas C.R., Rod-riguez C., Calle E.E., Thun M.J. (2002). Vitamin C, vitamin E, and multivitaminsupplement use and stomach cancer mortality in the cancer prevention study II co-hort. Cancer Epidemiol. Biomarkers Prev., 11(1), 35-41.

182. Jacobs E.J., Henion A.K., Briggs P.J., Connell C.J., McCullough M.L.,Jonas C.R., Rodriguez C., Calle E.E., Thun M.J. (2002). Vitamin C and vitamin Esupplement use and bladder cancer mortality in a large cohort of US men and wom-en. Am. J. Epidemiol., 156(11), 1002-1010.

183. Jaloszynski P., Jaruga P., Olinski R., Biczysko W., Szyfter W., Nagy E.,Moller L., Szyfter K. (2003). Oxidative DNA base modifications and polycyclic ar-omatic hydrocarbon DNA adducts in squamous cell carcinoma of larynx. Free Rad-ic. Res., 37(3), 231-240.

184. Jaloszynski P., Kujawski M., Czub-Swierczek M., Markowska J., SzyfterK. (1997). Bleomycin-induced DNA damage and its removal in lymphocytes ofbreast cancer patients studied by comet assay. Mutat. Res., 385(3), 223-233.

185. James K.M., Smith R.A., Murphy M.P. (2004). Antioxidant and prooxi-dant properties of mitochondrial coenzyme Q. Arch. Biochim.-Biophys., 423(1),47-56.

186. Jaraš nien D., Šimaitis A. (2003). Oksidacinis stresas ir endotelin dis-funkcija. Medicina, 39(12), 1151-1157.

LIETUVOS MOKSLAS

129

187. Jarvinen K., Soini Y., Kahlos K., Kinnula V.L. Kinnula V.L. (2002). Over-expression of gamma-glutamylcysteine synthetase in human malignant mesothelio-ma. Human Pathol., 37(7), 748-755.

188. Jaworska M., Gillissen A., Scharling B., Wichenburg D., Scultze-Wern-inghaus G. (1995). N-acetylcysteine: functional oxygen radical scavenger in vitroand ex vivo in monocytes and neutrophilic granulocytes of patients with CO PD.Pneumonologie, 49(10), 534-545.

189. Jung K., Reszka R. (2001). Mitochondria as subcellular targets for clini-cally useful anthracyclines. Adv. Drug Deliv. Rev., 49(1-2), 87-105.

190. Kaczmarek P., Buczynski A., Niemirowicz J., Gnitecki W., Kocur E.,Karpinski J. (2001). Lipids peroxidation in platelets in patients with bladder cancertreated with Mycobacterium suspension. Pol. Merkuriusz Lek., 11(66), 484-486.

191. Kalinina E.V., Saprin A.N., Solonika V.S., Shcherbak N.P., ChermnykhN.S., Pirutian L.A. (2001). Role of the antioxidant system and redox-dependentregulation of transcription factors bcl-2 and p53 in forming resistance of human K-562 erythroleukemia cells to doxorubicin. Vopr. Oncol. 47(5), 595-600.

192. Kamat A.M., Lamm D.L. (2002). Chemoprevention of bladder cancer.Urol. Clin. North Am., 29(1), 157-168.

193. Kappus H., Reinhold C. (1990). Inhibition of bleomycin-induced toxic ef-fects by antioxidants in human malignant melanoma cells. Adv. Exp. Med. Biol.,264, 345-348.

194. Karbownik M., Reiter R.J. (2000). Antioxidative effects of melatonin inprotection against cellular damage caused by ionizing radiation. Proc. Soc. Exp. Bi-ol. Med., 225(1), 9-22.

195. Karp D.D.,Tsao A.S., Kim E.S. (2003). Nonsmall-cell lung cancer:chemoprevention studies. Semin. Thorac. Cardiovasc. Surg., 15(4), 405-420.

196. Kastan M.B., Canman C.E., Leonard C.J. (1995). P53, cell cycle controland apoptosis: implications in cancer. Cancer Metastasis Rev., 14(1), 3-15.

197. Katsoulis K., Kontakiotis T., Leonardopoulos I., Kotsovili A., LegakisIN., Patakas D. (2003). Serum total antioxidant status in severe exacerbation ofasthma: correlation with the severity of the disease. J. Asthma, 40(8), 847-854.

198. Kaugars G.E., Silverman S.Jr., Lovas J.G., Brandt R.B., Riley W.T., DaoQ., Singh V.N., Gallo J. (1994). A clinical trial of antioxidant supplements in thetreatment of oral leukoplakia. Oral Surg. Oral Med. Oral Pathol., 78(4), 462-8.

199. Kaya H., Delibas N., Serteser M., Ulukaya E., Ozkaya O. (1999). The ef-fect of melatonin on lipid peroxidation during radiotherapy in female rats. Strahlen-ther. Onkol., 175(6), 285-288.


130

200. Kelloff G.J., Johnson J.R., Crowell J.A., Boone C.W., DeGeorge J.J.,Steele V.E., Mehta M.U., Temeck J.W., Schmidt W.J., Burke G., et al. (1995). Ap-proaches to the development and marketing approval of drugs that prevent cancer.Cancer Epidemiol. Biomarkers Prev., 4(1), 1-10.

201. Khadir A., Verreault J., Averill D.A. (1999). Inhibition of antioxidantsand hyperthermia enhance bleomycin-induced cytotoxicity and lipid peroxidationin Chinese hanister ovary cells. Arch. Biochem. Biophys., 370(2), 163-175.

202. Khoshyomn S., Manske G.C., Lew S.M., Wald S.L., Penar P.L. (2000).Synergistic action of genistein and cisplatin on growth inhibition and cytotoxicityof human medulloblastoma cells. Pediatr. Neurosurg., 33(3), 123-131.

203. Khynriam D., Prasad S.B. (2003). Cisplatin-induced genotoxic effectsand endogenous glutathione levels in mice bearing ascites Dalton’s lymphoma.Mutat. Res., 526(1-2), 9-18.

204. Khyshiktuev B.S., Khyshiktueva N.A., Darenskaya S.D. (1996). The ef-fect of surgery on free-radical reactions in patients with lung cancer. Vopr. Onkol.,42(6), 23-27 (rus.).

205. Kidd P.M. (1997). Glutathione: systemic protectant against oxidative andfree radical damage. Altern. Med. Rev., 2, 155-176.

206. Kirvelien V., Prasmickait L., Kadziauskas J., Bonnett R., Djelal B.D.,Juodka B. (1997). Post-exposure processes in Temoporfin-photosensitized cells invitro: reliance on energy metabolism. J. Photochem. Photobiol. B., 41(1-2), 173-180.

207. Kirvelien V., Sadauskait A., Kadziauskas J., Sasnauskien S., Juodka B.(2003). Correlation of death modes of photosensitized cells with intracellular ATPconcentration. FEBS Lett., 553, 167-172.

208. Kitamura Y., Ota T., Matsuoka Y., Tooyama I., Kimura H., ShimohamaS., Nomura Y., Gebicke-Haerter P.J., Taniguchi T. (1999). Hydrogen peroxide-in-duced apoptosis mediated by P53 protein in glial cells. Glia, 25(2), 154-164.

209. Klaunig J.E., Kamendulis L.M. (2004). The role of oxidative stress in car-cinogenesis. Annu. Rev. Pharmacol. Toxicol., 44, 239-267.

210. Klaunig J.E., Xu Y., Isenberg J.S., Bachowski S., Kolaja K.L., Jiang J.,Stevenson D.E., Walborg E.F. Jr. (1998). The role of oxidative stress in chemicalcarcinogenesis. Environ. Health Perspect., 106(Suppl.1), 289-295.

211. Kolanjiappan K., Ramachandran C.R., Manoharan S. (2003). Biochemi-cal changes in tumor tissues of oral cancer patients. Clin. Biochem., 36(1), 61-65.

212. Kong O., Lillehei K.O. (1998). Antioxidant inhibitors for cancer therapy.Med. Hypotheses, 51(5), 405-409.

LITERAT RA

131

213. Korotkina R.N., Spiridonova O.V., Matskevich G.N., Kucheinik A.Sh.,Kunitsyn A.G., Vishnevskii A.A., Karelin A.A. (2003). Study of total lipid peroxi-dation and antioxidant activity in pulmonary and mediastinal malignant and benigntumor tissue. Bull. Exp. Biol. Med., 136(3), 283-285.

214. Kroning R., Lichtenstein A.K., Nagami G.T. (2000). Sulfur-containingamino acids decrease cisplatin cytotoxicity and uptake in renal fubule epithelial celllines. Cancer Chemother. Pharmacol., 45(1), 43-49.

215. Ku inskien Z. (2001). Laisvieji radikalai, j dalyvavimas lig patogene-z je ir antioksidacin gynyba. Gydymo menas, 3(66), 74-76.

216. Kucuk O. (2002). New opportunities in chemoprevention research. Can-cer Invest., 20(2), 237-245.

217. Kumar B., Jha M.N., Cole W.C., Bedford J.S., Prasad K.N. (2001). D-al-pha-tocopheryl succinate (vitamin E) enhances radiation-induced chromosomaldamage levels in human cancer cells, but reduces it in normal cells. J. Am. Coll.Nutr., 21(4), 339-343.

218. Kurbacher C.M., Wagner U., Kolster B., Andreotti P.E., Krebs D., Bruck-ner H.W. (1996). Ascorbic acid (vitamin C) improves the antineoplastic activity ofdoxorubicin, cisplatin, and paclitaxel in human breast carcinoma cells in vitro. Can-cer Lett., 103(2), 183-189.

219. Kurie J.M., Lee J.S., Khuri F.R., Mao L., Morice R.C., Lee J.J., WalshG.L., Broxson A., Lippman S.M., Ro J.Y., Kemp B.L., Liu D., Fritsche H.A., XuX., Lotan R., Hong W.K. (2000). N-(4-hydroxyphenyl) retinamide in the chemo-prevention of squamous metaplasia and dysplasia of the bronchial epithelium. Clin.Cancer Res., 6(8), 2973-2979.

220. Kutorga V., Didžiapetrien J., Šukelien D., Dži vien .D., Graželien G.,Prasmickien G., Damarackis B., Kurtinaitis J., Zdanauskas S., Breivis P. (1991).Navik chemoterapija: ieškojimai, dabartis ir ateitis. Lietuvos medicina, 2, 20-24.

221. Labriola D., Livingston R. (1999). Possible interactions between dietaryantioxidants and chemotherapy. Oncology, 13(7), 1003-1012.

222. Ladas E.J., Jacobson J.S., Kennedy D.D., Teel K., Fleischauer A., KellyK.M. (2004). Antioxidants and cancer therapy: a systematic review. J. Clin. Oncol.,22(3), 517-528.

223. Lam P.K., To E.W., Chan E.S., Liew C.T., Lung I.W., King W.K. (2001).In vitro inhibition of head and neck cancer-cell growth by human recombinant in-terferon-alpha and 13-cis retinoic acid. Br. J. Biomed. Sci., 58(4), 226-229.

224. Lambert C., Thews O., Biesalski H.K., Vaupel P., Kelleher D.K., Frank J.(2002). 2-Methoxyestradiol enhances reactive oxygen species formation and in-

LIETUVOS MOKSLAS

132

creases the efficacy of oxygen radical generating tumor threatment. Eur. J. Med.Res., 30, 7(9), 404-414.

225. Lamm D.L., Riggs D.R., Shriver J.S., von Gilder P.F., Pach J.F., DeltavenJ.I. (1994). Megadose vitamin in bladder cancer: a double-blind clinical trials. J.Urol., 151, 21-28.

226. Lamson D.W., Brignall M.S. (1999). Antioxidants in cancer therapy; theiractions and interactions with oncologic therapies. Altern. Med. Rev., 4(5), 304-329.

227. Lamson D.W., Brignall M.S. (2000). Antioxidants and cancer therapy II:quick reference guide. Altern. Med. Rev., 5(2):152-163.

228. Lases E.C., Duurkens V.A., Gerritsen W.B., Haas F.J. (2000). Oxidativestress after lung resection therapy: A pilot study. Chest, 117(4), 999-1003.

229. Lay A.J., Jinag X.M., Kisker, O., Flynn E., Underwood A., Condron R.,Hogg P.J. (2000). Phosphoglycerate kinase acts in tumor angiogenesis as a disul-phide reductase. Nature, 408(6814), 869-873.

230. Lee I.M. (1999). Antioxidant vitamins in the prevention of cancer. Proc.Assoc. Am. Physicians, 111(1), 10-15.

231. Lee J.S., Lippman S.M., Benner S.E., Lee J.J., Ro J.Y., Lukeman J.M.,Morice R.C., Peters E.J., Pang A.C., Fritsche H.A. Jr., Hong W.K. (1994). Random-ized placebo-controlled trial of isotretinoin in chemoprevention of bronchial squa-mous metaplasia. J. Clin. Oncol., 12(5), 937-945.

232. Lefaix J.L., Delanian S., Leplat J.J., Tricaud Y., Martin M., Nimrod A.,Baillet F., Daburon F. (1996). Successful treatment of radiation-induced fibrosis us-ing Cu/Zn-SOD and Mn-SOD: an experimental study. Int. J. Radiat. Oncol. Biol.Phys., 35(2), 305-312.

233. Li N., Zhai Y., Oberley T.D. (1999). Two distinct mechanisms for inhibi-tion of cell growth in human prostate carcinoma cells with antioxidant enzyme im-balance. Free Radic. Biol. Med., 26(11-12), 1554-1568.

234. Lieberman R. (2002). Chemoprevention of prostate cancer: current statusand future directions. Cancer Metast. Rev., 21, 297-309.

235. Liede K., Hietanen J., Saxen L., Haukka J., Timonen T., Hayrinen-Im-monen R., Heinonen O.P. (1998). Long-term supplementation with alpha-toco-pherol and beta-carotene and prevalence of oral mucosal lesions in smokers. OralDis., 4(2), 78-83.

236. Lin M.T., Wang M.X., Liaw K.Yi., Lee Po-H., Chien S.F., Tsai Jir-S., Lin-Shiau S.-Yn. (2001). Superoxide dismutase in hepatocellular carcinoma affects pa-tient prognosis. Hepato-Gastroenterology, 48, 1102-1105.


133

237. Liotti F.S., Bodo M., Talesa V. (1983). Stimulating effect of ascorbinic ac-id on ascites tumor cell multiplication in vitro. J. Cancer Res. Clin. Oncol., 106(1),69-70.

238. Lippman S.M., Batsakio J.G., Toth B.B., Weber R.S., Lee J.J., MartinJ.W., Hays G.L., Goepfert H., Hong W.K. (1993). Comparison of low-dose isotret-inoin with beta-carotene to prevent oral carcinogenesis. N. Engl. J. Med., 328(1),15-20.

239. Lippman S.M., Parkinson D.R., Itri L.M., Kavanagh J.J., Peredes-Espino-za M., Delgadillo-Madrueno F., Paredes-Casillas P., Hong W.K., Holdenev E., Kra-koff L. (1995). 13-cis retinoic acid plus interferon-a-2: highly active systemic ther-apy for squamous cell carcinoma of the cervix. J. Natl. Cancer Inst., 84, 241-245.

240. Lippman S.M., Spitz M.R. (2001). Lung cancer chemoprevention: an in-tegrated approach. J. Clin. Oncol., 19(Suppl.18), 74S-82S.

241. Lissoni P., Barni S., Cattaneo G., Tancini G., Esposti G., Esposti D., Fras-chini F. (1991). Clinical results with the pineal hormone melatonin in advancedcancer resistant to standard antitumor therapies. Oncology, 48(6), 448-450.

242. Lissoni P., Meregalli S., Fossati V., Paolorossi F., Barni S., Tancini G.,Frigerio F. (1994). A randomized study of immunotherapy with low-dose subcuta-neous interleukin-2 plus melatonin vs chemotherapy with cisplatin and etoposide asfirst-line therapy for advanced non-small cell lung cancer. Tumori, 80(6), 464-467.

243. Lissoni P., Paolorossi F., Tancini G., Ardizzoia A., Barni S., Brivio F.,Maestroni G.J., Chilelli M. (1996). A phase II study of tamoxifen plus melatonin inmetastatic solid tumour patients. Br. J. Cancer, 74(9), 1466-1468.

244. Lissoni P., Rovelli F., Malugani F., Bucovec R., Conti A., Maestroni G.J.(2001). Anti-angiogenic activity of melatonin in advanced cancer patients. Neu-roendocrinol. Lett., 22(1), 45-47.

245. Lissoni P., Tancini G., Paolorossi F., Mandala M., Ardizzoia A., MaluganiF., Giani L., Barni S. (1999). Chemoneuroendocrine therapy of metastatic breastcancer with persistent thrombocytopenia with weekly low-dose epirubicin plus me-latonin: a phase II study. J. Pineal Res., 26(3), 169-173.

246. Lockwood K., Moesgaard S., Hanioka T., Folkers K. (1994). Apparentpartial remission of breast cancer in high risk parients supplemented with nutrition-al antioxidants, essencial fatty acid and coenzyme Q10. Mol. Aspects Med., Suppl.15, 5231-5240.

247. Lockwood K., Moesgaard S., Yamamoto T., Folkers K. (1995). Progresson therapy of breast cancer with vitamin Q10 and the regression of metastases. Bio-chem. Biophys. Res. Commun., 212(1), 172-177.

LITERAT RA

134

248. Lui Q.Y., Tan B.K. (2003). Relationship between antioxidant activitiesand doxorubicin – induced lipid peroxidation in P388 tumour cells and heart andliver in mice. Clin. Exp. Pharmacol. Physiol., 30(3), 185-188.

249. Luna M.C., Ferrario A., Wong S., Fisher A.M., Gomer C.J. (2000). Photo-dynamic therapy-mediated oxidative stress as a molecular switch for the temporalexpression of genes ligated to the human heat shock promoter. Cancer Res., 60(6),1637-1644.

250. Lund E.L., Quistorff B., Spang-Thomsen M., Kristjansen P.E. (1998). Ef-fect of radiation therapy on small-cell lung cancer is reduced by ubiquinone intake.Folia Microbiol., 43(5), 505-506.

251. Mackerras D., Irwig L., Simpson J.M., Weisberg E., Cardona M., WebsterF., Walton L., Ghersi D. (1999). Randomized double-blind trial of beta-caroteneand vitamin C in women with minor cervical abnormalities. Br. J. Cancer, 79(9-10),1448-1453.

252. Maestroni G.J., Conti A. (1996). Melatonin in human breast cancer tissue:association with nuclear grade and estrogen receptor status. Lab. Invest., 75(4),557-561.

253. Malaker K., Anderson B.J., Beecroft W.A., Hodson D.I. (1991). Manage-ment of oral mucosal dysplasia with beta-carotene and retinoic acid: a pilot cross-over study. Cancer Detect. Prev., 15(5), 335-340.

254. Malins D.C., Haimanot R. (1991). Major alterations in the nucleotidestructure of DNA in cancer of the female breast. Cancer Res., 51(19), 5430-5432.

255. Manetta A., Schubbert T., Chapman J., Schell M.J., Peng Y.M., Liao S.Y.,Meyskens F.J. J. (1996). beta-Carotene treatment of cervical intraepithelial neopla-sia: a phase II study. Cancer Epidemiol. Biomarkers Prev., 5(11), 929-32.

256. Manju V., Kalaivani Sailaja J., Nalini N. (2002). Circulating lipid peroxi-dation and antioxidant status in cervical cancer patients: a case-control study. Clin.Biochem., 35(8), 621-625.

257. Manoharan S., Kolanjiappan K., Kayalvizhi M., Sethupathy S. (2002).Lipid peroxidation and antioxidant status in cervical cancer patients. J. Biochem.Mol. Biol. Biophys., 6(3), 225-227.

258. Mantovani G., Maccio A., Madeddu C., Mulas C., Massa E., Astara G.,Ferreli L., Mudu M.C., Gramignano G., Murgia V., Lusso M.R., Mocci M., CardiaA., Mura L. (2002). Phase II study of subcutaneously administered interleukin-2 incombination with medroxyprogesterone acetate and antioxidant agents as mainte-nance treatment in advanced cancer responders to previous chemotherapy. OncolRep., 9(4), 887-896.

LIETUVOS MOKSLAS

135

259. Mantovani G., Madeddu C., Gramignano G., Lusso M.R., Mocci M.,Massa E., Ferreli L., Astara G., Maccio A., Serpe R. (2003). Subcutaneous interleu-kin-2 in combination with medroxyprogesterone acetate and antioxidants in ad-vanced cancer responders to previous chemotherapy: phase II study evaluatingclinical, quality of life, and laboratory parameters. J. Exp. Ther. Oncol., 3(4), 205-219.

260. Marnett L.J. (1999). Lipid peroxidation–DNA damage by malondyalde-hyde. Mutat. Res., 424(1-2), 83-95.

261. Marnett L.J. (2000). Oxyradicals and DNA damage. Carcinogenesis,21(3), 361-370.

262. Marshall H.E., Merchant K., Stamler J.S. (2000). Nitrosation and oxida-tion in the regulation of gene expression. FASEB J., 14(13), 1889-1990.

263.Marshall J.R. (1999). Beta-carotene: a miss for epidemiology. J. Natl.Cancer Inst., 91(24), 2068-2069.

264. Marshall K.A., Reiter R.J., Poeggeler B., Aruoma O.I., Halliwell B.(1996). Evaluation of the antioxidant activity of melatonin in vitro. Free Radic. Bi-ol. Med., 21(3), 307-315.

265. Mates J.M., Sanchez-Jimenez F.M. (2000). Role of reactive oxygen spe-cies in apoptosis: implications for cancer therapy. Int. J. Biochem. Cell Biol., 32(2),157-170.

266. Mayne S.T., Cartmel B., Baum M., Shor-Posner G., Fallon B.G., BriskinK., Bean J., Zheng T., Cooper D., Friedman C., Goodwin W.J. Jr. (2001). Random-ized trial of supplement beta-carotene to prevent second head and neck cancer.Cancer Res., 61(4), 1457-1463.

267. Mayne S.T., Graham S., Zheng T. (1991). Dietary retinol: prevention orpromotion of carcinogenesis in humans? Cancer Causes and Control, 2, 443-450.

268. McKeown-Eyssen G., Holloway C., Jazmaji V., Bright-See E., Dion P.,Bruce W.R. (1988). A randomized trial of vitamins C and E in the prevention of re-currence of colorectal polyps. Cancer Res., 48(16), 4701-4705.

269. Melnikova V.O., Bezdetnaya L.N., Brault D., Potapenko A.Y., GuilleminF. (2000). Enhancement of meta-tetrahydroxyphenylchlorin-sensitized photody-namic treatment on human tumor xenografts using a water-soluble vitamin E ana-logue, Trolox. Int. J. Cancer, 88(5), 798-803.

270. Meuillet E., Stratton S., Prasad Cherukuri D., Goulet A.C., Kagey J., Por-terfield B., Nelson M.A. (2004). Chemoprevention of prostate cancer with seleni-um: an update on current clinical trials and preclinical findings. J. Cell Biochem.,91(3), 443-458.


136

271. Meyskens F.L. Jr., Surwit E., Moon T.E., Childers J.M., Davis J.R., DorrR.T., Johnson C.S., Alberts D.S. (1994). Enhancement of regression of cervical in-traepithelial neoplasia II (moderate dysplasia) with topically applied all-trans-retin-oic acid: a randomized trial. J. Natl. Cancer Inst., 86(7), 539-543.

272. Migliore L., Frenzilli G., Nesti C., Fortaner S., Sabbioni E. (2002). Cyto-genetic and oxidative damage induced in human lymphocytes by platinum, rhodi-um and palladium compounds. Mutagenesis, 17(5), 411-417.

273. Mikalauskait D. (1999). Apie optimal antioksidant poreik . Labora-torin medicina, 3, 43-44.

274. Mikalauskait D. (2003). Profilaktin mityba. Vilnius: UAB Petro ofse-tas, 112.

275. Mills E.E. (1988). The modifying effect of beta-carotene on radiation andchemotherapy induced oral mucositis. Br. J. Cancer, 57(4), 416-417.

276. Minotti G., Menna P., Salvatorelli E., Cairo G., Gianni L. (2004). Anthra-cyclines: molecular advances and pharmacologic developments in antitumor activi-ty and cardiotoxicity. Pharmacol. Rev., 56(2), 185-229.

277. Miodini P., Fioravanti L., Di Fronzo G., Cappelletti V. (1999). The twophyto-oestrogens genistein and quercetin exert different effects on oestrogen recep-tor function. Br. J. Cancer, 80(8), 1150-1155.

278. Mirvish S.S. (1996). Inhibition by vitamins C and E of in vivo nitrosationand vitamin C occurence in the stomach. Eur. J. Cancer Prev., 5 (Suppl. 1), 131-136.

279. Miyajima A., Nakashima J., Tachibana M., Nakamura K., Hayakawa M.,Murai M. (1999). N-acetylcysteine modifies cis-dichlorodiammineplatinum-in-duced effects in bladder cancer cells. Jpn. J. Cancer Res., 90(5), 565-570.

280. Miyamoto Y., Koh Y.H., Park Y.S., Fujiwara N., Sakiyama H., MisonouY., Ookawara T., Suzuki K., HonkeK., Taniguchi N. (2003). Oxidative stresscaused by inactivation of glutatione peroxidase and adaptive response. Bioch.Chem., 384 (4), 567-574.

281. Mohammad R.M., Al-Katib A., Aboukameel A., Doerge D.R., Sarkar F.,Kucuk O. (2003). Genistein sensitizes diffuse large cell lymphoma to CHOP (cy-clophosphamide, doxorubicin, vincristine, prednisone) chemotherapy. Mol. CancerTher., 2(12), 1361-1368.

282. Monteiro H.P., Stern A. (1996). Redox modulation of tyrosine phosphory-lation-dependent signal transduction pathways. Free Radic. Biol. Med., 21(3), 323-333.

283. Morgan W.F., Day J.P., Kaplan M.I., McGhee E.M., Limoli C.L. (1996).Genomic instability induced by ionizing radiation. Radiat. Res., 146(3), 247-258.

LITERAT RA

137

284. Morse M.A., Stoner G.D. (1993). Cancer chemoprevention: principlesand prospects. Carcinogenesis, 14(9), 1737-1746.

285. Moschos M.P. (2000). Selenoprotein P. Cell Mol. Life Sci., 57(13-14),1836-1845.

286. Murakami A., Nakamura Y., Tanaka T., Kawabata K., Takahashi D., Ko-shimizu K., Ohigashi H. (2000). Suppression by citrus auraptene of phorbol ester-and endotoxin-induced inflammatory responses: Role of attenuation of leukocyteactivation. Carcinogenesis, 21, 1843-1850.

287. Muto Y., Moriwaki H., Ninomiya A., Adachi S., Saito A., Takasaki K.T.,Tanaka T., Tsurumi K., Okuno M., Tomita E., Nakamura T., Kojima T. (1996). Pre-vention of second primary tumors by an acyclic retinoid, polyprenoic acid in pa-tients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N. Engl.J. Med., 334(24), 1561-1567.

288. Nair J., Furstenberger G., Burger F., Marks F., Bartsch H. (2000). Promu-tagenic etheno-DNA adducts in multistage mouse skin carcinogenesis: correlationwith lipoxygenase-catalyzed arachidonic acid metabolism. Chem. Res. Toxicol.,13(8), 703-709.

289. Navis I., Sriganth P., Premalatha B. (1999). Dietary curcumin with cispl-atin administration modulates tumour marker indices in experimental fibrosarcoma.Pharmacol. Res., 39(3), 175-179.

290. Neal R., Matthews R.H., Lutz P., Ercal N. (2003). Antioxidant role of N-acetyl cysteine isomers following high dose irradiation. Free Radic. Biol. Med.,34(6), 689-695.

291. Neri B., Fiorelli C., Moroni F., Nicita G., Paoletti M.C., Ponchietti R.,Raugei A., Santoni G., Trippitelli A., Grechi G. (1994). Modulation of human lym-phoblastoid interferon activity by melatonin in metastatic renal cell carcinoma. Aphase II study. Cancer, 73(12), 3015-3019.

292. Niles R.M. (2002). The use of retinoids in the prevention and treatment ofskin cancer Expert Opin. Pharmacother, 3(3), 299-303.

293. Nisar S., Feinfeld D.A. (2002). N-acetylcysteine as salvage therapy in cis-platin nephrotoxicity. Renal Failure, 24(4), 529-533.

294. Nunoshila T., Obata F., Boss H., Oikawa S., Mari T., Kawanishi S.,Yamamoto K. (1999). Role of iron and superoxide dismutase for gereration of hy-droxyl radical, oxidative DNA lesions and mutagenesis in Escherichia coli. J. Biol.Chem., 274(49), 34832-34837.

295. Oberley L.W. (2001). Anticancer therapy by expression of superoxidedismutase. Antiox. Redox Signaling, 3(3), 461-472.

LIETUVOS MOKSLAS

138

296. Oberley T.D. (2002). Oxidative damage and cancer. Am. J. Pathol.,160(2), 403-408.

297. Oberley T.D., Zhong W., Szweda L. I., Oberley L.W. (2000). Localizationof antioxidant enzymes and oxidative damage products in normal and malignantprostate epithelium. Prostate, 44(2), 144-155.

298. Oikawa S., Furukawaa A., Asada H., Hirakawa K., Kawanishi S. (2003).Catechins induce oxidative damage to cellular and isolated DNA through the gen-eration of reactive oxygen species. Free Radic. Res., 37(8), 881-890.

299. Oikawa S., Kawanski S. (1994). Site-specific DNA damage at GGG se-quence by oxidative stress may accelerate telomere sharting. FEBS Lett., 453, 365-368.

300. Olas B., Wachowicz B., Buczynski A. (2000). Vitamin C suppresses thecisplatin toxicity on blood platelets. Anticancer Drugs, 11(6), 487-493.

301. Omenn G.S., Goodman G.E., Thornquist M.D., Balmes J., Cullen M.R.,Glass A., Keogh J.P., Meyskens F.L., Valanis B., Williams J.H., Barnhart S., Cher-niack M.G., Brodkin C.A., Hammar S. (1996). Risk factors for lung cancer and forintervention effects in CARET, the beta-carotene and retinol efficacy trial. J. Natl.Cancer Inst., 88(21), 1550-1559.

302. Omenn G.S., Goodman G.E., Thornquist M.D., Balmes J., Cullen M.R.,Glass A., Keogh J.P., Meyskens F.L., Valanis B., Williams J.H., Barnhart S., Ham-mar S. (1996). Effects of combination of beta-carotene and vitamin A on lung can-cer and cardiovascular disease. N. Engl. J. Med., 334(18), 1150-1155.

303. Pace A., Savarese A., Picardo M., Maresca V., Pacetti U., Del Monte G.,Biroccio A., Leonetti C., Jandolo B., Cognetti F., Bove L. (2003). Neuroprotectiveeffect of vitamin E supplementation in patients treated with cisplatin chemotherapy.J. Clin. Oncol., 21(5), 927-931.

304. Paganelli G.M., Biasco G., Brandi G., Santucci R., Gizzi G., Villani V.,Cianci M., Miglioli M., Barbara L. (1992). Effect of vitamins A, C and E supple-mentation on rectal cell proliferation in patients with colorectal adenomas. J. Natl.Cancer Inst., 84(1), 47-51.

305. Pan W.H., Wang C.Y., Huang S.M., Yeh SY., Lin W.G., Lin D.I., LiawY.F. (1993). Vitamin A, vitamin E or beta-carotene status and hepatitis B-relatedhepatocellular carcinoma. Ann. Epidemiol., 3(3), 217-224.

306. Pani G., Bedogni B., Anzevino R., Colavitti R., Palazzotti B., Borrello S.,Galeotti T. (2000). Deregulated manganese superoxide dismutase expression on re-sistance to oxidative injury in p53-deficient cells. Cancer Res., 60(16), 4054-4660.

307. Papadimitrakopoulou V.A., Hong W.K. (1997). Retinoids in head andneck chemoprevention. Proc. Soc. Exp. Biol. Med., 216(2), 283-290.


139

308. Park C.H. (1988). Vitamin C in leukemia and preleukemia cell growth.Prog. Clin. Biol. Res., 259, 321-330.

309. Park E.J., Pezzuto J.M. (2002). Botanicals in cancer chemoprevention.Cancer Metast. Rev., 21(3-4), 231-255.

310. Park E.S., Kim S.D., Lee M.H., Lee H.S., Lee I.S., Sung J.K., Yoon Y.S.(2003). Protective effects of N-acetylcysteine and selenium against doxorubicintoxicity in rats. J. Vet. Sci., 4(2), 129-136.

311. Park T.K., Lee J.P., Kim S.N., Choi S.M., Kudelka A.P., Kavanagh J.J.(1998). Interferon-alpha 2a, 13-cis-retinoic acid and radiotherapy for locally ad-vanced carcinoma of the cervix: a pilot study. Eur. J. Gynecol. Oncol., 19(1), 35-38.

312. Parnes H.L., House M.G., Kagan J., Kausal D.J., Lieberman R. (2004).Prostate cancer chemoprevention agent development: the National Cancer Institute,Division of Cancer Prevention portfolio. J. Urol., 171(2), s68-s74.

313. Pastorino U., Infante M., Maioli M., Chiesa G., Buyse M., Firket P., Ros-mentz N., Clerici M., Soresi E., Valente M., Belloni P.A., Ravasi G. (1993). Adju-vant treatment of stage I lung cancer with high dose vitamin A. J. Clin. Oncol.,11(7), 1216-1222.

314. Patrick L. (2000). Beta-carotene: the controversy continues. Altern. Med.Rev., 5(6), 530-545.

315. Patterson R.E., White E., Kristal A.R., Neuhouser M.L., Potter J.D.(1997). Vitamin supplements and cancer risk: the epidemiologic evidence. CancerCauses and Control, 8(5), 786-802.

316. Pawliczak R. (2003). The role of radical oxygen in airway inflammation.Pol. Merkuriuz Lek., 14(84), 493-496.

317. Pawlikowski M., Winczyk K., Karasek M. (2002). Oncostatic action ofmelatonin: facts and question marks. Neuroendocrinol. Lett., 23 (Suppl.1), 24-29.

318. Peng Y.M., Peng Y.S., Childers J.M., Hatch K.D., Roe D.J., Lin Y., Lin P.(1998). Concentration of carotenoids, tocopherols, and retinol in paired plasma andcervical tissue of patients with cervical cancer, precancer and noncancerous diseas-es. Cancer Epidemiol. Biomarkers Prev., 7(4), 347-350.

319. Perotti C., Casas A., Del C Batlle A.M. (2002). Scavengers protection ofcells against ALA-based photodynamic therapy-induced damage. Lasers Med. Sci.,17(4), 222-229.

320. Peters L.J. (1996). Radiation therapy tolerance limits. For one or for all?(Janeway Lecture). Cancer, 77(11), 2379-2385.

321. Peto R. (1981). Cancer, cholesterol, carotene, and tocopherol. Lancet,2(8237), 97-98.

LITERAT RA

140

322. Philips L.L. (1956). Effect of free radicals on chromosomes of barley.Science, 227, 375-381.

323. Phillips R.W., Kikendall J.W., Luk G.D., Willis S.M., Murphy J.R., May-donovitch C., Bowen P.E., Stacewicz-Sapuntzakis M., Wong R.K. (1993). β-Caro-tene inhibits rectal mucosal ornithine decarboxylase activity in colon cancer pa-tients. Cancer Res., 53(16), 3723-3725.

324. Pittet J.F., Mackersie R.C., Martin T.R., Matthay M.A. (1997). Biologicalmarkers of acute lung injury: prognostic and pathogenetic significance. Am. J.Respir. Crit. Care Med., 155(4), 1187-1205.

325. Policastro L., Molinari B., Larcher F., Blanco P., Podhajcer O.L., CostaC.S., Rojas P., Duran H. (2004). Imbalance of antioxidant enzymes in tumor cellsand inhibition of proliferation and malignant features by scavenging hydrogen per-oxide. Mol. Carcinog., 39(2), 103-113.

326. Prasad A.S., Kucuk O. (2002). Zinc in cancer prevention. Cancer Metast.Rev. 21, 291-295.

327. Prasad K.N., Cole W., Prasad J.E. (1999). Multiple antioxidant vitaminsas an adjunct to standart and experimental therapies. J. Oncol., 31, 4-11.

328. Prasad K.N., Cole W.C., Kumar B., Prasad K.C. (2001). Scientific ratio-nale for using high-dose multiple micronutrients as an adjunct to standard and ex-perimental cancer therapies. J. Am. Coll. Nutr., 20(5), 450S-463S.

329. Prasad K.N., Hernandez C., Edwards-Prasad J., Nelson J., Borus T., Rob-inson W.A. (1994). Modification of the effect of tamoxifen, cis-platin, DTIC, andinterferon-alpha 2b on human melanoma cells in culture by a mixture of vitamins.Nutr. Cancer, 22(3), 233-245.

330. Prasad K.N., Kumar R. (1996). Effect of individual and multiple antioxi-dant vitamins on growth and morphology of human nontumorigenic and tumori-genic parotid acinar cells in culture. Nutr. Cancer, 26(1), 11-19.

331. Prasad M.P., Mukundan M.A. Krishnaswamy K. (1995). Micronuclei andcarcinogen DNA adducts as intermediate end points in nutrient intervention trial ofprecancerous lesions in the oral cavity. Eur. J. Cancer B. Oral. Oncol., 31B(3), 155-159.

332. Prasmickien G., Šukelien D., Sta iokien L., Didžiapetrien J., At-ko ius V., Valuckas K. (1996). Lipid peroksidacijos poky iai navikuose, kombin-uojant porfirin kilm s fotosensibilizatorius su gama spinduliais. Kn.: Šiuolaikin sspindulin s diagnostikos ir spindulin s terapijos optimizacija. Šventoji, 134-135.

333. Pryor W.A., Stahl W., Rock C.L. (2000). Beta carotene: from biochemis-try to clinical trials. Nutrition Reviews, 58(2 Pt 1), 39-53.

LIETUVOS MOKSLAS

141

334. Punnonen K., Ahotupa M., Asaishi K., Hyoty M., Kudo R., Punnonen R.(1994). Antioxidant enzyme activities and oxidative stress in human breast cancer.J. Cancer Res. Clin. Oncol., 120(6), 374-377.

335. Puscas I., Baican M., Coltan H., Puscas C., Domuta G. (1999). Erythro-cyte superoxide dismutase activity in patients with digest cancer: adjuvant diagno-sis test. Cancer Lett., 143(1), 95-98.

336. Qureshi A.A., Mo H., Packer L., Peterson D.M. (2000). Isolation andidentification of novel tocotrienols from rice bran with hypocholesterolemic, anti-oxidant, and antitumor properties. J. Agric Food Chem., 48(8), 3130-3140.

337. Radi R. (1998). Peroxynitrite reaction and diffusion in biology. Res. Tox-icol., 11(7), 720-721.

338. Rajeswari N., Ahuja Y.R., Malini U., Chandrashekar S., Balakrishna N.,Rao K.V., Khar A. (2000). Risk assessment in first degree female relatives of breastcancer patients using the alkaline Comet assay. Carcinogenesis, 21(4), 557-561.

339. Randerath K., Reddy M.V., Disher R.M. (1986). Age – and tissue – relat-ed DNA modifications in untreated rats: detection by 32P-postalabeling assay andpossible significance for spontaneous tumor induction and aging. Carcinogenesis,7(9), 1615-1617.

340. Rautalahti M.T., Virtamo J.R., Taylor P.R., Heinonen O.P., Albanes D.,Haukka J.K., Edwards B.K., Karkkainen P.A., Stolzenberg-Solomon R.Z., Hut-tunen J. (1999). The effects of supplementation with alpha-tocopherol and beta-car-otene on the incidence and mortality of carcinoma of the pancreas in a randomized,controlled trial. Cancer, 86(1), 37-42.

341. Ray G., Batra S., Shukla N.K., Deo S., Raina V., Ashok S., Husain S.A.(2000). Lipid peroxidation, free radical production and antioxidant status in breastcancer. Breast Cancer Res. Treat., 59(2), 163-170.

342. Ray G., Husain S.A. (2002). Oxidants, antioxidants and carcinogenesis.Indian J. Exp. Biol., 40(11), 1213-1232.

343. Rayman M.P. (2000). The importance of selenium to human health. Lan-cet, 356(9225), 233-241.

344. Recchia F., Sica G., Casucci D., Rea S., Gulino A., Frati L. (1998). Ad-vanced carcinoma of the pancreas: phase II study of combined chemotherapy, beta-interferon, and retinoids. Am. J. Clin. Oncol., 21(3), 275-278.

345. Reddy B.S. (1996). Micronutrients as chemopreventive agents. In: Princi-ples of chemoprevention (eds.) Stewart B.W., McGregor D., Kleihues P. IARC Sci.Publ. 1(139), 221-235.


142

346. Reiter R.J., Tan D.X., Manchester L.C., Qi W. (2001). Biochemical reac-tivity of melatonin with reactive oxygen and nitrogen species: a review of the evi-dence. Cell Biochem. Biophys., 34(2), 237-256.

347. Reiter R.J., Tan D.X., Osuna C., Gitto E. (2000). Actions of melatonin inthe reduction of oxidative stress: a review. J. Biomed. Sci., 7(6), 444-458.

348. Ren W., Qiao Z., Wang H., Zhu L., Zhang L. (2003). Flavonoids: promis-ing anticancer agents. Med. Res. Rev., 23(4), 519-534.

349. Rhyu M.S. (1995). Telomeres, telomerase, and immortality. J. Natl. Can-cer Inst., 87(12), 884-894.

350. Riordan H.D., Hunninghake R.B., Riordan N.H., Jackson J.J., Meng X.,Taylor P., Casciari J.J., Gonzalez M.J., Miranda-Massari J.R., Mora E.M., RosarioN., Rivera A. (2003). Intravenous ascorbic acid: protocol for its application anduse. P. R. Health Sci. J., 22(3), 287-290.

351. Riordan N.H., Riordan H.D., Casciari J.P. (2000). Clinical and experi-mental experencies with intravenous vitamin C. J. Orthomol. Med., 5, 201-213.

352. Riordan N.H., Riordan H.D., Meng X., Li Y., Jackson J.A. (1995). Intra-venous ascorbate as a tumor cytotoxic chemotherapeutic agent. Med. Hypotheses,44(3), 207-213.

353. Romney S.L., Ho G.Y., Palan P.R., Basu J., Kadish A.S., Klein S.,Mikhail M., Hagan R.J., Chang C.J., Burk R.D. (1997). Effects of beta-caroteneand other factors on outcome of cervical dysplasia and human papillomavirus in-fection. Gynecol. Oncol., 65, 484-492.

354. Roncucci L., Donato P.D., Carati L., Ferrari A., Perini M., Bertoni G., Be-dogni G., Paris B., Svanoni F., Girola M., et al. (1993). Antioxidant vitamins orlactulose for the prevention of recurrence of colorectal adenomas Dis. Colon Rec-tum, 36(3), 227-234.

355. Roomi M.W., House D., Eckert-Maksic M., Maksic Z.B., Tsao C.S.(1998). Growth suppression of malignant leukemia cell line in vitro by ascorbic ac-id (vitamin C) and its derivatives. Cancer Lett., 122(1-2), 93-99.

356. Ros-Bullon M.R., Sancher-Pedreno P., Martinez-Liarte J.H. (1999).Whole blood glutathione peroxidase activity in melanoma patients. Cancer Letters,144(1), 25-30.

357. Sabitha K.E., Shyamaladevi C.S. (1999). Oxidant and antioxidant activitychanges in patients with oral cancer and treated with radiotherapy. Oral Oncol.,35(3), 273-277.

358. Sankaranarayanan R., Mathew B., Varghese C., Sudhakaran P.R., MenonV., Jayadeep A., Nair M.K., Mathews C., Mahalingam T.R., Balaram P., Nair P.P.

LITERAT RA

143

(1997). Chemoprevention of oral leucoplakia with vitamin A and beta-carotene: anassessment. Oral. Oncol., 33(4), 231-236.

359. Scambia G., Ranelletti F.O., Panici P.B., De Vincenzo R., Bonanno G.,Ferrandina G., Piantelli M., Bussa S., Rumi C., Cianfriglia M., et al. (1994). Quer-cetin potentiates the effect of adriamycin in a multidrug-resistant MCF-7 humanbreast-cancer cell line: P-glycoprotein as a possible target. Cancer Chemother.Pharmacol., 34(6), 459-464.

360. Schmidinger M., Budinsky A.C., Wenzel C., Piribauer M., Brix R.,Kautzky M., Oder W., Locker G.J., Zielinski C.C., Steger G.G. (2000). Glutathionein the prevention of cisplatin induced toxicities. A prospectively randomized pilottrial in patients with head and neck cancer and non small cell lung cancer. WienKlin. Wochenschr., 112(14), 617-623.

361. Schmidt-Ullrich R.K., Dent P., Grant S., Mikkelsen R.B., Valerie K.(2000). Signal transduction and cellular radiation responses. Radiat. Res., 153(3),245-257.

362. Schrauzer G.N. (2000). Anticarcinogenic effects of selenium. Cell. Mol.Life Sci., 57(13-14). 1864-1873.

363. Schuller P., Puttmann S., Mucke R., Senner V., Schafer U., Kisters K.,Micke O. (2001). From the radiolysis of water to the role of trace elements in radio-biology and clinical radiation therapy: following a logical chain. Trace Elem. Elec-troly. 18(4), 186-192.

364. Schwartz J.L. (1995). Molecular and biochemical control of tumorgrowth following treatment with carotenoids or tocopherols. In: Prasad K.N., San-tamaria L., Williams R.M. (eds.): „Nutrients in Cancer Prevention and Treatment“.Totowa, NJ: Humana Press, 287-316.

365. Seidman M.D., Quirk W.S., Shirwany N.A. (1999). Reactive oxygen me-tabolites, antioxidants and head and neck cancer. Head Neck, 21(5), 467-479.

366. Seifter E., Rettura A., Padowar J., Sevenson S.M. (1984). Vitamin A andbeta carotene as adjunctive therapy to tumor excision radiation therapy and chemo-therapy. In: Prasad K.N. (eds.): Vitamins, nutrition and cancer. Basel: Karger, 1-19.

367. Senturker S., Tschirret-Guth R., Morrow J., Levine R., Shacter E. (2002).Induction of apoptosis by chemotherapeutic drugs without generation of reactiveoxygen species. Arch. Biochem. Biophys., 397(2), 262-272.

368. Sewerynek E., Reiter R.J., Melchiori D., Ortiz G.G., Lewinski A. (1996).Oxidative damage in the liver induced by ischemia-reperfusion: protection by me-latonin. Hepatogastroenterology, 43(10), 898-905.

369. Shabad L.M. (1969). Endogennyje kancerogennyje veš estva. Moskva:Medicina, 262 (rus.).

LIETUVOS MOKSLAS

144

370. Shackelford R.E., Kaufmann W.K., Paules R.S. (2000). Oxidative stressand cell cycle checkpoint function. Free Radic. Biol. Med., 28(9), 1387-1404.

371. Shacter E., Weitzman S.A. (2002). Chronic inflammation and cancer. On-cology, 16 (2), 217-226.

372. Shacter E., Williams J.A., Hinson R.M., Senturher S., Lee YJ. (2000).Oxidative stress interferes with cancer chemotherapy: inhibition of lymphoma cellapoptosis and phagocytosis. Blood, 96(1), 307-313.

373. Sharma R.A., Gescher A.J., O‘Byrne K.J., Steward W.P. (2001). Familiardrugs may prevent cancer. Postgrad. Med. J., 77(910), 492-497.

374. Sheikh-Hamad D., Timmins K., Jalali Z. (1997). Cisplatin-induced renaltoxicity: possible reversal by N-acetylcysteine treatment. J. Am. Soc. Nephrol.,8(10), 1640-1644.

375. Shibutani S., Suzuki N., Laxmi Y.R., Schild L.J., Divi R.L., GrollmanA.P., Poirier M.C. (2003). Identification of tamoxifen-DNA adducts in monkeystreated with tamoxifen. Cancer Res., 63(15), 4402-4406.

376. Shukla V.K., Adukia T.K., Singh S.P., Mishra C.P., Mishra R.N. (2003).Micronutrients, antioxidants, and carcinoma of the gallbladder. J. Surg. Oncol.,84(1), 31-35.

377. Siems W.G., Sommerburg O., Grune T. (2000). Erythrocyte free radicaland energy metabolism. Clin. Nephrol., 53(1), 9-17.

378. Sies H. (1991). Oxidative stress: from basic research to clinical applica-tion. Am. J. Med., 91(3C), 31S-38S.

379. Skrzydlewska E., Kozuszko B., Sulkowska M., Bogdan Z., KozlowskiM., Snarska J., Puchalski Z., Sulkowski S., Skrzydlewski Z. (2003). Antioxidantpotential in esophageal, stomach and colorectal cancers. Hepatogastroenterology,50(49), 126-131.

380. Smyth J.F., Bowman A., Perren T., Wilkinson P., Prescott R.J., QuinnK.J., Tedeschi M. (1997). Glutathione reduces the toxicity and improves quality oflife of women diagnosed with ovarian cancer treated with cisplatin: results of adouble-blind, randomised trial. Ann. Oncol., 8(6), 569-573.

381. Solanki V., Rana R.S., Slaga T.J. (1981). Diminution of mouse epidermalsuperoxide dismutase and catalase activities by tumor promoters. Carcinogenesis,2(11), 1141-1146.

382. Soleas G.J., Grass L., Josephy P.D., Goldberg D.M., Diamandis E.P.(2002). A comparison of the anticarcinogenic properties of four red wine polyphe-nols. Clin. Biochem., 35(2), 119-124.

383. Sporn M.B., Newton D.L. (1979). Chemoprevention of cancer with retin-oids. Fed. Proc., 38, 2528-2534.


145

384. Sporn M.B., Suh N. (2000). Chemoprevention of cancer. Carcinogenesis,21(3), 525-530.

385. Stadtman E.R., Oliver C.H. (1991). Metal-catalysed oxidation of proteins.Physiological canseguences. J. Biol. Chem., 266(4), 2005-2008.

386. Stich H.F., Hornby A.P., Mathew B., Sankaranarayanan R., Nair M.K.(1988). Response of oral leucoplakias to the administration of vitamin A. CancerLett., 40(1), 93-101.

387. Streckyt G., Didžiapetrien J., Graželien G., Prasmickien G., Šuke-lien D., Kazlauskait N., Characiejus D., Grici t L., Rotomskis R. (1999). Ef-fects of photodynamic therapy in combination with Adriamycin. Cancer Lett.,146(1), 73-86.

388. Stukas R. (1999). Sveika mityba. Vilnius: Vilniaus universiteto leidykla,102.

389. Subramaniam S., Subramaniam S., Shyamala Devi C.S. (1994). Erythro-cyte antioxidant enzyme activity in CMF treated breast cancer patients. CancerBiochem. Biophys., 14(3), 177-182.

390. Sugiyama S., Yamada K., Hayakawa M., Ozawa T. (1995). Approachesthat mitigate doxorubicin-induced delayed adverse effects on mitochondrial func-tion in rat hearts; liposome-encapsulated doxorubicin or combination therapy withantioxidant. Biochem. Mol. Biol. Int., 36(5), 1001-1007.

391. Šukelien D., Dži vien D., Didžiapetrien J., Grici t L., Domkien V.,Šekštelien E. (1989). Benzolselenono r gšties darini poveikis cheminei kancero-genezei bei navik augimui. Onkologija, 8, 59-64.

392. Šukelien D., Dži vien D., Didžiapetrien J., Stripinien D. (1992). Theinfluence of some amino acids and amino sugars hydroselenates on development oftransplanted tumours. In: Synthesis and Research of Physiological Active Sub-stances: Abstracts of the Meeting of Estonian, Latvian and Lithuanian Pharmacolo-gists. Vilnius, 93-95.

393. Šukelien D., Prasmickien G., Aleknavi ien B., Aleknavi ius E.,Graželien G., Didžiapetrien J. (2000). Spindulin s ir enzim terapijos poveikisantioksidacinei sistemai. Medicina, 36(8), 850-854.

394. Sun J., Chen Y., Li M., Ge Z. (1998). Role of antioxidant enzymes on ion-izing radiation resistance. Free Radic. Biol. Med., 24, 586-593.

395. Surh Y.-J., Hurh Y.-J., Kang J.-Y., Lee E., Kong G., Lee S.J. (1999). Res-veratrol, an antioxidant present in red wine induces apoptosis in human promyelo-cytic leukemia (HL-60) cells. Cancer Lett., 140(1-2), 1-10.

396. Tamini R.M., Lagiou P., Adami H.-O., Trichopoulous D. (2002). Prospectsfor chemoprevention of cancer. Journal of Internal Medicine, 251(4), 286-300.

LITERAT RA

146

397. Tan D.X., Manchester L.C., Burkhardt S., Sainz R.M., Mayo J.C., KohenR., Shohami E., Huo Y.S., Hardeland R., Reiter R.J. (2001). N1-acetyl-N2-formyl-5-methoxykynuramine, a biogenic amine and melatonin metabolite, functions as apotent antioxidant. FASEB J., 15(12), 2294-2296.

398. Tanaka T. (1994). Cancer chemoprevention by natural products (review).Oncology Reports. 1, 1139-1155.

399. Tanaka T., Mori M. (1996). Inhibition of colon carcinogenesis by non-nu-tritive constituents in foods. J. Toxicol. Pathol., 9, 139-149.

400. Taper H.S., de Gerlache J., Lans M., Roberfroid M. (1987). Non-toxic po-tentiation of cancer chemotherapy by combined C and K3 vitamin pre-treatment.Int. J. Cancer, 40(4), 575-579.

401. Taper H.S., Keyeux A., Roberfroid M. (1996). Potentiation of radiothera-py by nontoxic pretreatment with combined vitamins C and K3 in mice bearing sol-id transplantable tumor. Anticancer Res., 16(1), 499-503.

402. Teicher B.A., Schwartz J.L., Holden S.A., Ara G., Northey D. (1994). Invivo modulation of several anticancer agents by beta-carotene. Cancer Chemother.Pharmacol., 34(3), 235-241.

403. Terry P., Lagergren J., Ye W., Nyren O., Wolk A. (2000). Antioxidantsand cancers of the esophagus and gastric cardia. Int. J. Cancer, 87(5), 750-754.

404. Tobatabaie T., Vasquez-Weldon A., Moore D.R., Katake Y. (2003). Freeradicals and the pathogenesis of type 1 diabetes, beta-cell cytokine-mediated freeradicals generation via cycloxygenase-2. Diabetes, 6(7), 1130-1137.

405. Toh Y., Kuninaka S., Oshiro T., Ikeda Y., Nakashima H., Baba H.,Kohnoe S., Okamura T., Moni M., Sugimachi K. (2000). Overexpression of man-ganese superoxide dismutase mRNA may correlate with aggressiveness in gastricand colorectal adenocarcinomas. Int. J. Oncol., 17(1), 107-112.

406. Tolnai S., Morgan J.F. (1966). Studies on the in vitro antitumor activity offatty acids. VII. Effect of amino acid-fatty acid salts. Can. J. Biochem. Physiol.,44(6), 979-981.

407. Toma S., Benso S., Albanese E., Palumbo R., Cantoni E., Nicolo G.,Mangiante P. (1992). Treatment of oral leucoplakia with beta-carotene. Oncology,42(2), 77-81.

408. Toma S., Micheletti A., Giacchero A., Coialbu T., Collecchi P., EspositoM., Rotondi M., Albanese E., Cantoni E. (1991). Selenium therapy in patients withprecancerous and malignant oral cavity lesions: preliminary results. Cancer Detect.Prev., 15(6), 491-494.

LIETUVOS MOKSLAS

147

409. Toma S., Palumbo R., Raffo P., Spadini N., Rosso R. (1994). 13-cis-retin-oic acid, beta-carotene and other anti-oxidant agents in chemoprevention and thera-py of head and neck cancer. Eur. J. Cancer Prev., 3(4), 374-377.

410. Toma S., Raffo P., Isnardi L., Palumbo R. (1999). Retinoids in lung can-cer chemoprevention and treatment. Ann. Oncol., 10(5), 95-S102.

411. Torrisi R., Decensi A., Formelli F., Camerini T., De Palo G. (2001).Chemoprevention of breast cancer with fenretinide. Drugs, 61(7), 909-918.

412. Torun M., Yardim S., Gonenc A., Sargin H., Menevse A., Simsek B.(1995). Serum beta-carotene, vitamin E, vitamin C and malondialdehyde levels inseveral types of cancer. J. Clin. Pharm. Ther., 20(5), 259-263.

413. Toyokuni S. (1999). Reactive oxygen species-induced molecular damageand its application in pathology. Pathol. Int., 49(2), 91-102.

414. Traber M.G., Arai H. (1999). Molecular mechanisms of vitamin E trans-port. Annu. Rev. Nutr., 19, 343-355.

415. Traber M.G., Packer L. (1995). Vitamin E: beyond antioxidant function.Am. J. Clin. Nutr., 62(6), 1501S-1509S.

416. Tsao A.S., Kim E.S., Hong W.K. (2004). Chemoprevention of cancer. CACancer J. Clin., 54, 150-180.

417. Turesky R.J. (2002). Heterocyclic aromatic amine metabolism, DNA ad-duct formation, mutagenesis, and carcinogenesis. Drug Metab. Rev., 34(3), 625-650.

418. Turley J.M., Ruscetti F.W., Kim S.J., Fu T., Gou F.V., Birchenall-RobertsM.C. (1997). Vitamin E succinate inhibits proliferation of BT-20 human breast can-cer cells: increased binding of cyclin A negatively regulates E2F transactivation ac-tivity. Cancer Res., 57(13), 2668-2675.

419. Turunen M., Olsson J., Dallner G. (2004). Metabolism and function ofCoenzyme Q. Biochim. Biophys. Acta, 1660 (1-2), 171-179.

420. Uberti D., Yavin E., Gil S., Ayasola K.R., Goldfinger N., Rotter V. (1999).Hydrogen peroxide induces nuclear translocation of p53 and apoptosis in cells oli-godendroglia origin. Brain Res. Mol. Brain Res. 65(2), 167-175.

421. Uleckien S. (1999). Organiniai seleno junginiai – chemin s kanceroge-nez s inhibitoriai. Sveikatos mokslai, 2, 49-51.

422. Uleckien S., Domkien V. (1997). Chemopreventive effects of novel or-ganic selenate on experimentally induced tumours. In: Theory and Practice of Can-cer Prevention: Materials of Conference. Vilnius, 88-89.

423. Uleckien S., Domkien V. (2001). V žio chemoprofilaktikos aktualijos.Kn.: V žio profilaktikos problemos. Monografija/Sud. E.Moncevi i t -Eringien .Vilnius: Lietuvos mokslas, 33 kn., 58-68.


148

424. Uleckiene S., Domkiene V. (2003). Investigation of ethyl alcohol and βcarotene effect on two models of carcinogenesis. Acta Biol. Hung., 54(1), 89-93.

425. Uleckien S., Grici t L., Šukelien D., Didžiapetrien J. (2003). Evalua-tion of original selenium containing organic compounds for potential chemopre-ventive properties in experimental lung cancer. In: International Conference „Lungcancer, standards and new trends”: Abstracts, Vilnius, 14.

426. Vadgama J.V., Wu Y., Shen D., Hsia S., Block J. (2000). Effect of seleni-um in combination with Adriamycin or Taxol on several different cancer cells. An-ticancer Res., 20(3A), 1391-1414.

427. Vainio H. (2000). Chemoprevention of cancer: lessons to be learned frombeta-carotene trials. Toxicol. Lett., 112-113, 513-517.

428. Valgimigli M., Merli E., Malagutti P., Soukhomovskaja O., Cicchitelli G.,Macri G., Ferrari R. (2003). Endothelial disfunction and chronic coronary syn-dromes: evidence for a pathogenetic role of oxidative stress. Arch. Biochem. Bio-phys., 420(2), 255-261.

429. Valuckas K., Burneckis A. (1997). Spindulin s terapijos raida Lietuvosonkologijos centre. Medicina, 33 (pr.10), 114-116.

430. Valuckas K.P., Didžiapetrien J., Atko ius V., Grici t L., Lukšien Ž.,Zaleckait L., Rotomskis R., Smilgevi ius V. (1993). Laser gamma irradiation andchemotherapy in treatment of experimental tumors sensitized by porphyrins. Opti-cal methods for tumor treatment and detection: mechanisms and techniques in pho-todynamic therapy II, Dougherty. Proc. SPIE, 1881, 76-83.

431. Van der Werff Y.D., van der Houwen H.K., Heijmans P.J., Duurkens V.A.,Leusink H.A., van Heesewijk H.P., de Boer A. (1997). Postpneumonectomy pul-monary edema. A retrospective analysis of incidence and possible risk factors.Chest, 111(5), 1278-1284.

432. Van Rijn J., van den Berg J. (1997). Flavonoids as enhancers of x-ray-in-duced cell damage in hepatoma cells. Clin. Cancer Res., 3(10), 1775-1779.

433. Van Zandwijk N., Dalesio O., Pastorino U., de Vries N., van Tinteren H.(2000). EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in pa-tients with head and neck cancer or lung cancer. J. Natl. Cancer Inst., 92(12), 977-986.

434. Van Zandwijk N., Pastorino U. (2003). Chemoprevention of lung cancer:soon daily practice. Expert Rev. Anticancer Ther., 3(1), 91-98.

435. Vento R.D., D’Alessandro N., Giuliano M., Lauricella M., Carabillo M.,Tesoriere G. (2000). Induction of apoptosis by arachidonic acid in human retinoblas-toma Y79 cells: involvement of oxidative stress. Exp. Eye. Res., 70(4), 503-517.

LITERAT RA

LITERAT Ë RA - elibrary.lt · 116 25. Bishayee A., Sarkar A., Chatterjee M. (2000). Further...

Documents

Transcript of LITERAT Ë RA - elibrary.lt · 116 25. Bishayee A., Sarkar A., Chatterjee M. (2000). Further...